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Organophosphates (OPs), such as nerve agents and insecticides, potently inhibit
acetylcholinesterase (AChE). Oximes, such as the currently FDA approved oxime 2-PAM,
remove the OP from the inhibited enzyme. 2-PAM is effective against select OPs and cannot
effectively pass the blood-brain barrier to attenuate OP induced CNS damage. Our laboratory has
synthesized a series of substituted phenoxyalkyl pyridinium oximes (Patent number: 9,227,937)
that have demonstrated increased survival rates compared to 2-PAM. This research investigated
1) in vitro oxime reactivation of rat, human, and guinea pig serum BChE after inhibition by
nerve agent and insecticidal OPs; 2) in vitro determination of reactivation kinetic rate constants
for OP inhibited human and rat serum BChE and electric eel AChE after inhibition by a sarin
surrogate and paraoxon; 3) intranasal delivery of oximes to reactivate brain AChE in vivo after
inhibition by a sarin surrogate. Novel oxime 15 demonstrated significant broad spectrum
reactivation of OP-inhibited rat serum BChE while novel oxime 20 demonstrated significant
broad spectrum reactivation of OP-inhibited human serum BChE. All tested oximes were poor
reactivators of OP-inhibited guinea pig serum BChE. Kinetic analysis of reactivation for NIMP
and paraoxon human and rat serum BChE and electric eel AChE demonstrated differences in the

second order rate constants. Oxime 20 demonstrated reactivation efficiency for both NIMP and
paraoxon inhibited rat and human serum BChE and electric eel AChE more effectively than 2PAM. Intranasal delivery of either oxime 20 or 2-PAM showed attenuation of NIMP-inhibited
brain AChE inhibition in select brain regions and select time points. Oxime 20 demonstrated a
larger window of effectiveness but neither oxime attenuated brain AChE inhibition in the
hindbrain for any time point or for any brain region at the ten minute time point. These data
suggest that reactivation of OP-inhibited BChE may be contributing to the observed increases in
survival seen with our oximes. Novel oxime 20 demonstrated reactivation efficacy towards both
BChE and AChE inhibited enzyme and a rapid entry into the brain after intranasal delivery.
Having an oxime that can be effective in a multitude of ways would be of great value to medical
and military personnel.
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CHAPTER I
INTRODUCTION
Organophosphate History and Usage
Organophosphorus compounds (OPs) are a diverse group of organic chemicals which
share a central phosphorus (P) atom and 3 other atoms with usually one double bond and two
single bonds. The atoms vary significantly surrounding the P atom but are most typically
oxygens (O) and sulfurs (S). The first OP to be synthesized was triethyl pyrophosphate in 1820
by Lassaigne followed shortly by tetraethyl pyrophosphate (TEPP) by de Clermont in 1854
(Chambers et al., 1992). It would not be until almost 100 years later when the insecticidal
properties of TEPP were revealed by Gerhard Schrader, a German scientist who was
investigating new insecticides. Schrader and others went on to develop some very toxic OP
compounds, namely tabun, sarin, soman, and parathion (Chambers et al., 1992). Tabun, sarin,
and soman showed high acute mammalian toxicity and volatility and were deemed too toxic to
be developed as insecticides but instead Schrader was instructed by the Nazi government to
develop them as chemical weapons to be used in warfare. These chemical weapons were called
nerve agents, as they attack the nervous system. Various nerve agents have been synthesized and
are categorized as ‘G’ agents or ‘V’ agents. The ‘G’ agents, which the ‘G’ stands for German,
consist of sarin (GB), tabun (GA), soman (GD), and cyclosarin (GF). The ‘V’ agents, namely
VX, which the ‘V’ stands for venomous, were originally synthesized by Britain and the United
States in the 1950s. Russian and Chinese derivatives of VX, VR and CVX, respectively, were
later synthesized (Antonijevic and Stojilijkovic, 2007). The G agents differ from the V agents
1

based on their chemical reactivity and toxicity. The G agents are clear liquids when fresh that
have high volatility whereas the V agents are viscous, have low volatility, are more
environmentally persistent, and are typically amber colored (Busl & Bleck, 2012). The V agents
are generally more toxic (rat iv LD50 7-10µg/kg for VX) than the G agents (rat iv LD50 4563µg/kg for sarin; John et al., 2009). Exposure primarily occurs from either inhalation or dermal
exposure.

Parathion was developed as an insecticide to counteract the growing insect resistance to
the then used organochlorine compounds. Various other OP pesticides were synthesized
throughout this timeframe and the OP class of compounds became the leading class of
insecticides for several decades until their replacement by the less toxic synthetic pyrethroids
(Chambers et al., 1992). OP pesticides in general are less toxic than the nerve agents; however,
there are a few insecticidal OPs that are quite toxic, such as parathion and phorate. One of the
differences between OP pesticides and nerve agents is that several OP pesticides, including
parathion and phorate, require metabolic activation from the double bonded sulfur attached to the
P atom (P=S) to the ‘oxon’ (paraoxon and phorate oxon, respectively) which replaces the sulfur
with an oxygen (P=O) and increases the toxicity of the compound (Hayes and Laws, 1991;
Chambers et al., 1992; Moyer et al., 2018). This reaction, called oxidative desulfuration, is
carried out by cytochrome P450 enzymes, a superfamily of phase 1 metabolizing enzymes found
throughout the entire body. The nerve agents already possess the P=O functionality and therefore
do not require any activation to be toxic.

Because of the high mammalian toxicity, relative ease of synthesis, and difficulty of
treatment associated with nerve agents and OP pesticides, they pose a risk for warfighters and
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civilians. They are an attractive choice for rogue dictators and terrorist groups and, despite being
banned for use in warfare, have been used in several instances. During the Iran-Iraq war, radical
dictator Saddam Hussein authorized the release of nerve and mustard agents on Iranian and
Kurdish populations, killing and injuring several thousand (Rose and Baravi, 1988; Balali-Mood
and Balali Mood, 2008; Smart, 1997). In Tokyo, 1995, the terrorist group Aum Shinrikyo
released sarin in the subway system killing several and wounding several thousand (Nagao et al.,
1997; Yokoyama et al.,1998). More recently, in 2013, nerve agents were used in the Syrian
conflict which resulted in the deaths of thousands of people (Dolgin, 2013; Pita and Domingo,
2014).

While the threat to life from exposure to OP nerve agents is significant, the likelihood of
exposure to such compounds is minimal. On the other hand, OP pesticides still present a problem
to clinicians in the United States and worldwide every year. OP insecticides are an effective and
inexpensive weapon against insects of all types and, despite decreased usage in the United States,
still represent 33% of the US pesticide market, which suggests exposure to OPs is still possible
(Atwood and Paisley-Jones, 2017). In underdeveloped countries, where training in the safe
handling and transport of pesticides is poor, and education on the harmful effects of pesticides is
limited, or where less stringent regulations on sale and storage of pesticides are present, or where
illegal sales of pesticides have occurred, accidental exposures and subsequent deaths of children
and agriculture workers happen fairly frequently (Chowdhury et al., 2008; Rosenthal, 2003;
Leverton et al., 2007; Tsai et al., 2007). Unfortunately, the more common scenario of pesticide
poisoning in developing countries is self ingestion to commit suicide, many of them being due to
OPs (Bertolote et al., 2006; Chugh et al., 1991; Eddleston, 2000; Fitzgerald et al., 1978). It is
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estimated that 200,000 people die every year to OP poisoning, mostly in underdeveloped
countries (Eddleston and Chowdhury, 2016).

Mechanism of Action
The toxicity of OPs can be largely attributed to the inhibition of acetylcholinesterase
(AChE; EC 3.1.1.7), a serine hydrolase responsible for hydrolyzing the neurotransmitter
acetylcholine (ACh), a chemical messenger that mediates several critical functions in both the
peripheral and central nervous systems. AChE is an exceptionally fast catalyst, operating at the
speed limit of biological catalysts, typically hydrolyzing ACh molecules with a kcat >104s-1 in a
two-step reaction that takes place in less than a millisecond (Quinn et al., 1987; Quinn et al.,
2017; Rosenberry, 1975). The first part of the reaction is a transesterification step, also called the
acetylation step, where the ester bond in the acetylcholine is attacked by the nucleophilic amino
acid serine in acetylcholinesterase, allowing the choline to depart and be recycled and the
formation of an acetyl-enzyme complex. The next step is a hydrolysis step, also called
deacetylation, where a water molecule is activated by the amino acid histidine, which attacks the
acetyl-enzyme complex and hydrolyzes the ester linkage. This reaction forms an acetic acid and
free enzyme (Mercey et al., 2012). OP inhibition mimics the acetylation step. The nucleophilic
serine attacks the phosphorus atom, allowing the leaving group to depart and forming a
phosphyl-serine complex. Hydrolysis of the OP is slow (hours to days) due to steric hindrances
of water molecule activation (Mercey et al., 2012); therefore, the enzyme is persistently inhibited
(see Figure 1-1 for ACh hydrolysis and OP inhibition of AChE).

4

Clinical Effects
The persistent OP induced inhibition of AChE leads to a buildup of Ach at neuronal
synapses and neuromuscular junctions. The actions of Ach on nicotinic and muscarinic
cholinergic receptors are amplified leading to a systemic cascade of toxic responses called the
cholinergic toxidrome. The clinical signs are diverse because of cholinergic innervation in the
parasympathetic and sympathetic nervous systems. Excessive stimulation of nicotinic receptors
at neuromuscular junction sites in skeletal muscle tissue causes muscle spasms, twitching, and
eventual paralysis of important respiratory muscles such as the intercostal muscles and the
diaphragm, while activation of muscarinic receptors leads to increased gland secretions at
salivary glands, mucosal glands, eye glands, depressed heart rate, bronchial airway constrictions,
and increased GI tract movement (Kellar, 2006). Clinical signs include shortness of breath, hypoand hypertension, tremors, seizures, muscle weakness, tachycardia and bradycardia, abdominal
cramps, miosis, salivation, lacrimation, urination, defecation (SLUD), laryngospasm,
bronchorrhea, rhinorrhea, and, ultimately, death occurs from respiratory failure (Antonijevic and
Stojilijkovic, 2007).

Clinical Treatment
There are three strategies to treat organophosphate poisoning. They consist of
anticholinergics, oximes, and anticonvulsants. The anticholinergic used is atropine sulfate.
Atropine is a competitive antagonist of muscarinic receptor subtypes which attenuates the
bradycardia and excessive gland secretions in the peripheral nervous system. However, atropine
is limited in its effectiveness because of its inability to reduce nicotinic receptor stimulation, its
limited effectiveness at attenuating muscarinic stimulation in the CNS, and the fact that high
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amounts of Ach in the case of high dose OP exposure can outcompete the atropine on muscarinic
receptors (Antonijevic and Stojilijkovic, 2007).

Anticonvulsants, such as diazepam or midazolam, are used to attenuate seizures. These
drugs belong to a class called benzodiazepines which are agonists of GABA receptors, the
primary inhibitory neurotransmitter in the brain. This increase of inhibitory drive causes a
hyperpolarization of neurons, making them less susceptible to cholinergic and glutamatergic
stimulation (Shih, 1991; McDonough et al., 2000). Oximes are used to remove the OP from the
enzyme in a process called reactivation because AChE becomes functional again and can
attenuate the excessive accumulation of Ach, allowing the body to return to homeostasis (Kusic
et al., 1991; Thiermann et al., 1997; Thiermann et al., 1999). There exists a variety of oxime
platforms. The currently approved oxime treatment in the United States is pyridinium-2aldoxime, or 2-PAM. Other pyridinium based oximes, such as the bis-pyridinium oximes TMB4, MMB-4, obidoxime (OBD), HI-6, and others, are used in other nations (see Figure 1-2 for
oxime structures). What makes oximes work is the formation of a nucleophilic oximate anion
(Mercey et al., 2012). These nucleophilic functional groups remove the electrophilic phosphoryl
group of the OP from the catalytic serine in AChE (see Figure 2 for oxime mechanism), which
causes the OP to form a stronger bond with the oxime than with the enzyme and depart, thus
restoring the enzyme’s function (Mercey et al., 2012).

Difficulties in Oxime Reactivator Treatment
Oximes are a critical component to the therapeutic regimen but there are several
limitations to oxime therapy which can present significant challenges to clinicians. The first is
that many OPs undergo a process called aging, which is the loss of an alkyl R group and the
formation of a negative charge on the OP-AChE enzyme complex (Quinn et al., 2017). This
6

negative charge causes a repulsion between the nucleophilic oxime and the inhibited enzyme,
preventing reactivation and forming a completely inactivated enzyme (Antonijevic and
Stojilijkovic, 2007). Currently, none of the oxime reactivator platforms can reactivate aged
AChE. Substantial differences exist between OPs with respect to half life-times required for
aging to occur. Research suggests that aged AChE occurs fastest with soman~2-3minutes
(Shafferman et al., 1996; Saxena et al., 1998; de Jong et al., 1984) whereas time of aging varies
significantly among sarin, VX, cyclosarin, and OP pesticides (Worek et al., 2004). It is suggested
that OPs with branched chain R groups, like isopropyl in sarin and pinacolyl in soman, are more
likely to age, and age faster, than those that do not have branched chain R groups, such as the
diethylphosphoryl moieties found in VX, VR, CVR and paraoxon (Shafferman et al., 1996;
Worek et al., 2004; Worek et al., 2013).

The other concern is that oximes possess varying efficacies towards the different OPs.
OPs are a diverse class of compounds and a single broad-spectrum reactivator has yet to be
found. Research shows that 2-PAM, TMB-4, obidoxime, HI-6, and HLö-7 are all efficient at
reactivating sarin and VX inhibited AChE (Johnson et al., 1970; Sidell et al., 1974; Inns et al.,
1983; Maksimovic et al., 1980), but they have varying efficacies with the other major OP nerve
agents (i.e., cyclosarin, tabun, soman), with HLö-7 being the most powerful at reactivating
soman, sarin, cyclosarin, and tabun (Worek et al., 1998; de Jong et al., 1989; Worek et al., 2005)
and MMB-4 being one of the poorest overall (Aurbek et al., 2006; Bartling et al., 2007). The
current oximes vary in their efficacies with OP insecticides as well, with 2-PAM being moderate
to poor against insecticidal OPs, as are HI-6 and HLö-7, and TMB-4 and obidoxime being the
most effective reactivators for OP insecticides (Jokanovic et al., 1995; Worek et al., 1996).
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Another problem with these oxime platforms is the inability to cross the blood brain
barrier (BBB) to any significant extent and regenerate brain inhibited AChE (Gallagher et al.,
2016; Kalasz et al., 2014; Lorke et al., 2008; Sakurada et al., 2003; Clement, 1979), thus brain
damage can still occur. Extensive research has been devoted to developing new oxime
reactivators that are broad spectrum and neuroprotective such as the substituted phenoxyalkyl
pyridinium oximes (Chambers et al., 2013), pro-2PAM (Bodor et al., 1975),
monoisonitrosoacetone—MINA (Skovira et al., 2010), and the neutral charged imidazole
aldoximes and N-substituted 2-hydroxyiminoacetamides (Rakesh et al., 2011), but nothing has
come forth as a replacement for 2-PAM or the other oximes.

Alternative Medical Strategies in Treating Organophosphates
Another challenge to clinicians is the potential for a high body load of OP after self
ingestion or from a lethal exposure to a nerve agent. A high dose exposure of OPs could
potentially mitigate the effectiveness of oxime therapy because of the likelihood that reinhibition
of the enzyme can occur, thus potentially requiring higher oxime doses that may not be well
tolerated in humans (Thiermann et al., 1999). Various medical countermeasures have come forth
to act as adjuncts to the current OP therapy. These treatment strategies consist of reversible
cholinesterase inhibitors and bioscavenger enzymes. The purpose of these is to improve CNS
AChE protection and to scavenge OP molecules in the circulation before the OPs have a chance
to reach critical target areas. These countermeasures can be very helpful as they reduce the ‘body
load’ of OP, which can prevent reinhibition of reactivated enzyme. Several of these strategies
investigated are given prophylactically, which means they are administered before exposure to
the OP. While not applicable towards civilians exposed accidentally, by terrorist attack or by
attempted suicide, these can be of value for our warfighters.
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Reversible Cholinesterase Inhibitors
Delivery of pyridostigmine bromide prophylactically in conjunction with posttreatment
atropine and 2-PAM has emerged as an effective strategy in treating soman and sarin exposure
(Leadbeater et al., 1985). Pyridostigmine bromide is a carbamate compound that reversibly
inhibits AChE in the periphery. By inhibiting AChE before OP exposure, some of the AChE is
shielded from irreversible inhibition by the OP. Additionally, since soman-inhibited AChE ages
very quickly, this treatment strategy has emerged as a way to circumvent that process. However,
very little pyridostigmine bromide enters the brain, leaving CNS AChE susceptible to OPinduced inhibition with the potential for brain damage to occur. Other reversible AChE inhibitors
have been brought forth that can more effectively cross the blood brain barrier, such as:
huperzine A, tacrine, physostigmine, and galantamine (Deshpande et al., 1986; Grunwald et al.,
1994; Fricke et al., 1994; Lallement et al., 2002; Albuquerque et al., 2006). While promising,
CNS side effects of these drugs have been noted and delivery of a drug prophylactically may not
always be feasible.

Use of Bio-Scavengers to Treat Organophosphates
Another strategy that has been investigated in OP treatment has explored the capability of
improving the detoxication of circulating OP molecules in the blood by bioscavengers, with the
hope of diminishing the amount of OP that can reach peripheral and neuronal AChE to cause
toxicity. The laboratory of Wolfe and company were the first to come up with the scavenger
concept. His work focused on increasing the cholinesterase pool in the blood (i.e., increasing the
first line of defense) by administration of fetal bovine serum (FBS) AChE. His work showed
protection to high levels of nerve agents in mice that were pretreated with FBS AChE (Wolfe et
al., 1987). Other scavengers have been investigated since then that are also able to neutralize
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OPs. These scavengers can be enzymes or antibodies that are stoichiometric (i.e., 1 enzyme to 1
OP molecule) or catalytic (enzymes that have a turnover rate; 1 enzyme to multiple OP
molecules). The catalytic scavengers are still in their infancy and are not the subject of this
manuscript and will be discussed no further.
The most promising stoichiometric scavenger that has been investigated is
butyrylcholinesterase (BChE). BChE is a serine hydrolase (EC 3.1.1.8) that is synthesized in the
liver. Humans have more total protein BChE than AChE--about 10x the amount of BChE
compared to AChE total protein (Lockridge, 2015), with the majority of BChE being found in
peripheral tissues like the blood and liver (Manoharan et al., 2007). BChE can be an effective
scavenger because of its larger active site that can accommodate a wide variety of ester
compounds (Li et al., 2005) and its lack of known physiological role; individuals who have a
silent BChE gene live normal, healthy lives but may be more susceptible to the adverse effects of
certain compounds like succinylcholine (Doenicke et al., 1963; Liddell et al., 1962). This lack of
known physiological role and ability to interact with a variety of toxic esters has led researchers
to believe that its role may be to serve as a protector of AChE, since many AChE inhibitors, such
as OPs, also inhibit BChE. Inhibition of BChE prevents AChE inhibition from these poisons.
Inhibition of BChE by OPs is very fast~107-109M-1min-1 (Masson et al., 2010), thus representing
one of the first lines of defense in the blood after OP exposure.
However, at high levels of toxicants, especially of OPs, BChE is saturated and easily
overwhelmed; therefore, significant amounts of OP can reach AChE and cause toxicity. To
counter this, pre-treatment with exogenous BChE has been an extensive area of research since
the 1990s. The US military successfully showed that administration of exogenous BChE
(significantly increasing the BChE pool) as a pre-treatment to organophosphates afforded
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protection to multiple animal models after exposure to lethal levels of nerve agents (Broomfield
et al., 1991; Ashani et al., 1991; Wolfe et al., 1992; Raveh et al., 1993). The US Department of
Defense (DoD) has since allocated millions of dollars to synthesize BChE as a prophylactic
treatment. It was labeled as an Investigational New Drug by the FDA in 2006 (Lenz et al., 2007)
and underwent phase I clinical trials by Baxter Health Corporation (Masson et al., 2010).
However, this line of treatment does have a few drawbacks. Since stoichiometric scavengers are
proteins that bind one molecule of nerve agent per one molecule of scavenger, the concentration
of administered scavenger needs to be high enough to neutralize a large amount of OP molecules
(Masson et al., 2010; Ashani and Pistinner, 2004). This dose is quite high, at least 200mg/70kg
for soman exposure protection (Ashani and Pistinner, 2004). Moreover, mass production of this
enzyme has proven to be a challenge and resulted in a very expensive treatment (Masson et al.,
2016), which limits the number of people that can receive it (1kg BChE~5000doses, Geyer et al.,
2010; Ashani Y, 2000). This treatment, while potentially having great benefit for first responders
or warfighters in an OP contaminated area, is limited in its ability to protect civilians and is more
than likely not economically feasible.
While substantial efforts have been devoted to developing recombinant BChE that can be
easier to mass synthesize (Zhang et al., 2016; Saxena et al., 2010; Huang et al., 2007; Chilukuri
et al., 2005; Chilukuri et al., 2008; Geyer et al., 2010; Parikh et al., 2010; Cerasoli et al., 2005;
Cerasoli et al., 2005), replicating the long circulatory half life of human plasma BChE, which is
about 11 days (Ostergaard et al., 1988), without eliciting an adverse immune response has
proven to be difficult (Rosenberg et al., 2015; Chilukuri et al., 2008; Chilukuri et al., 2008).
Having an enzyme with a long circulatory residence time with no immune response that can
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rapidly scavenge multiple OPs is highly desirable for a bioscavenger, but such an enzyme has yet
to be found.

Pseudo-Catalytic Scavengers
To combat the drawbacks of the stoichiometric scavengers, namely the high amounts of
enzyme needed, costs, and required advance knowledge of the attack, oxime reactivators have
been under investigation as potential tools to constantly regenerate inhibited BChE and allow for
consistent binding and degradation of inhibitor (Nachon et al., 2013; Aurbek et al., 2009), thus
providing a pseudo-catalytic, or oxime-assisted catalytic, function. BChE binds to the OP in a
process that destroys the OP and leaves the enzyme inhibited because of slow water molecule
activation to facilitate the hydrolysis of the OP. Oximes can remove the OP from the inhibited
enzyme and allow the newly regenerated enzyme to bind to additional OP molecules. This
constant inhibition and regeneration of BChE should mitigate severe signs of toxicity by
destroying significant amounts of OP in the circulation, thus affording protection to cardiac,
skeletal, and neuronal AChE by decreasing the amounts of OP reaching these targets. Oximeassisted catalysis with current and developmental oxime platforms for BChE has shown mixed
results (Radic et al., 2013; Katalinic et al., 2016; Busic et al., 2016; Konickx et al., 2013;
Aurbek et al., 2009). Having an antidote that can be effective against a wide variety of OPs and
have diverse therapeutic functions that is low cost would be of great benefit to medical and
military personnel.

Research Summary
Our laboratory has synthesized a series of novel phenoxyalkyl pyridinium oximes (US
Patent number: 9,227,937). These oximes, designed by the late Dr. Howard Chambers of
Mississippi State University, were synthesized with the intention as potential brain penetrating
12

AChE reactivators, which the current oxime platforms cannot do. These oximes have added
lipophilic moieties which should allow for increased entry into the brain. Previous research
completed in our laboratory has shown that these oximes have an ability to reactivate brain
AChE in vivo after inhibition by sarin and VX surrogates (Chambers et al., 2013; Chambers et
al., 2016), increase survivability and attenuate seizure-like behavior after exposure to sarin and
VX surrogates when compared to 2-PAM (Chambers et al., 2016), and attenuate OP induced
brain damage after exposure to paraoxon and sarin and VX surrogates (Pringle et al., 2018; Dail
et al., 2019). The research herein investigates these oximes as potential BChE reactivators with
the intention of identifying potential alternative oxime therapeutic mechanisms that may be
contributing to the increased survivability seen in vivo. In addition to this, intranasal delivery of
these oximes was investigated as a potential route of oxime administration to increase the
amount of oxime that can enter the brain and reactivate brain AChE.
BChE reactivation by oximes would allow for additional scavenging of OP molecules in
the circulation, thus potentially limiting the amount of OP molecules that can reach critical
cardiac and neuronal AChE and cause toxicity. Since there is no blood brain barrier (BBB)
present at the olfactory bulb that can restrict oxime access, intranasal delivery would allow for a
high amount of drug that can be delivered into the brain and potentially allow for a rapid
therapeutic onset.
Chapter 2 explores the ability of several of our novel oximes (OX1, OX9, OX12, OX13,
OX15, OX20, OX55, and OX62), in addition to the current oxime platforms used by various
nation states (2-PAM, TMB-4, MMB-4, obidoxime (OBD), and HI-6), to reactivate rat, human,
and guinea pig serum BChE in vitro after exposure to nitrophenyl isopropyl methylphosphonate
(NIMP; sarin surrogate), phthalimidyl isopropyl methylphosphonate (PIMP; sarin surrogate),
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nitrophenyl ethyl methylphosphonate (NEMP; VX surrogate), nitrophenyl cyclohexyl
methylphosphonate (NCMP; cyclosarin surrogate), diisopropyl methyl phosphonate (DFP;
commonly used sarin surrogate), as well as the insecticidal oxons paraoxon (PXN; metabolite of
parathion), phorate oxon and phorate oxon sulfoxide (PHO and PHOsox; metabolites of phorate).
The surrogates used in this study are representatives of some of the most relevant nerve agents
(sarin, VX, and cyclosarin) but are safer to work with while still displaying similar potency
patterns on AChE compared to the actual nerve agents (Coban et al., 2016). The benefit of these
surrogates is that they inhibit AChE and BChE with the same chemical moiety as the ‘parent’
nerve agents do (Meek et al., 2012; Ohta et al., 2006; Fukuto and Metcalf, 1959). The use of
insecticidal oxons serves to identify any broad spectrum efficacy capabilities that our oximes
possess against both nerve agent and insecticidal chemistries. Parathion and phorate are toxic OP
insecticides which could be used as potential alternative chemical agents in a terrorist scenario if
nerve agents are unavailable (Bajgar et al., 2015). The hypothesis for this project is that our
novel oximes are more effective BChE reactivators than the current pyridinium and bispyridinium oximes.
In chapter 3, oxime reactivation kinetics were performed with the lead oximes from
chapter 2 on rat and human serum BChE after inhibition by the sarin surrogate NIMP and
paraoxon, the insecticidal metabolite of parathion. Reactivation kinetics produces valuable
parameters of oxime effectiveness, such as the affinity and overall reactivity of the oxime for the
inhibited enzyme. These measures of affinity and reactivity can provide a quantitative
assessment on the effectiveness of an oxime before being tested in vivo. Since it is unethical to
test the efficacy of oximes in humans, animal models used for in vitro and in vivo testing are
invaluable tools for extrapolation of oxime efficacy to humans. Species differences are observed
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for the reactivation potential of oximes and the inhibitory potential of OPs on AChE (de Jong et
al., 1984; Worek et al., 2002; Worek et al., 2011; Luo et al., 2007). Therefore, the use of the rat,
which is the most common animal used in toxicity testing, was used in addition to human serum
to determine if any species related differences in BChE reactivation are present.
In chapter 4, intranasal delivery of novel oxime 20 and 2-PAM was tested as a potential
route of oxime administration to decrease OP induced brain AChE inhibition. One of the critical
setbacks of the current oxime platforms is the inability for them to cross the blood brain barrier
to any significant extent. Sakurada et al., 2003, demonstrated that 10% of 2-PAM administered
can pass through the blood brain barrier and potentially reactivate brain AChE; however, this
study only investigated 2-PAM alone treated animals. It is likely that in the presence of an OP
the amount of 2-PAM that could enter into the brain would be significantly less as most of the 2PAM would react with inhibited AChE in the periphery. Additionally, it is unclear if 10% is
enough to attenuate OP induced brain AChE inhibition and neurotoxicity. The lack of blood
brain barrier and the high vascularity in the nasal cavity should allow for entry of a high amount
of drug that can rapidly interact with the brain’s inhibited AChE, potentially mitigating CNS
neurotoxicity. An intranasally administered oxime, in conjunction with a peripherally
administered oxime, could produce system wide AChE protection.
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Figure 1.1

A) Mechanism of acetylcholine hydrolysis by AChE. (B) Mechanism of AChE
inhibition by organophosphorus nerve agents, aging, and reactivation by oximes.
Retrieved from Mercey et al., 2012.
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Figure 1.2

Chemical structures of currently used pyridinium and bis-pyridinium oxime
reactivators. Retrieved from Mercey et al., 2012.
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CHAPTER II
IN VITRO REACTIVATION OF RAT, HUMAN, AND GUINEA PIG SERUM
BUTYRYLCHOLINESTERASE BY NOVEL PHENOXYALKYL
PYRIDINIUM OXIMES AFTER INHIBITION
BY ORGANOPHOSPHORUS COMPOUNDS
Introduction
Organophosphorus compounds (OPs), such as chemical warfare nerve agents and some
insecticides, are highly toxic anticholinesterases that pose a threat to public health because of
their high potency, rapid onset of action, and resistance to therapeutics, making them an
attractive weapon for rogue nation states and terrorist groups. These compounds persistently
inhibit acetylcholinesterase (AChE) by phosphorylation of the catalytic serine hydroxyl group,
preventing its function of hydrolyzing the neurotransmitter acetylcholine, an important chemical
messenger in the peripheral and central nervous systems that governs critical skeletal, cardiac,
and brain functions. Inhibition of AChE leads to an accumulation of acetylcholine at neural
synapses, resulting in hyper-stimulation of cholinergic receptors throughout the body causing
seizures, respiratory distress, and paralysis (Ecobichon et al., 2001). Death may result if the
victim is left untreated.
Current methodology in the treatment of OP poisoning is the administration of atropine
sulfate, an anti-muscarinic that blocks the uncontrolled stimulation at peripheral muscarinic
receptor sites, and an oxime reactivator to regenerate the inhibited enzyme by removing the
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phosphate from the active site serine (Mercey et al., 2012). There are a variety of oxime
reactivators, namely the monopyridinium oxime 2-PAM and the bis-pyridinium oximes HI-6,
TMB-4, MMB-4, and obidoxime (OBD). Regeneration of the inhibited AChE by oximes is a
critical part of the therapeutic regimen to attenuate OP toxicity (Eyer, 2003; Kassa, 2002) but the
current oxime therapeutics display varying efficacies towards reactivating OPs (Antonijevic and
Stojilijkovic, 2007) and there is no single broad spectrum reactivator. The current oximes also
possess poor blood brain barrier penetration (Lorke et al., 2008) and therefore do not protect
against OP induced CNS damage.
Researchers have since been trying to find alternative ways to treat OP poisoning. A
promising approach has been the study of bioscavengers, with a large body of evidence
investigating butyrylcholinesterase (BChE) as a novel therapeutic target. BChE is a serine
hydrolase that interacts with a variety of endogenous and exogenous esters, including OPs
(Lockridge, 2015). It is this promiscuity that makes it an attractive pharmacological target, as
well as its large distribution throughout the body (Manoharan et al., 2007) and its lack of known
physiological role (Masson et al., 2010). Interaction of BChE with OPs causes destruction of
both substrate and enzyme in a 1:1 fashion (1 molecule of OP is destroyed by 1 molecule of
BChE) and prevents the OP from reaching AChE. This stoichiometric process can be easily
overwhelmed by high levels of toxicant but pretreatment with exogenous BChE from various
sources, thus greatly increasing the levels of BChE in the circulation, has proven to be an
effective modality at preventing OP toxicity and mortality in a variety of animal models (Lenz et
al., 2007). The major disadvantages to such a treatment are required knowledge of nerve agent
attack, the high amount of enzyme needed for protection (Masson et al., 2016; Ashani et al.,
2004), technological limitations for mass production of the enzyme (Saxena et al., 2010; Geyer
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et al., 2010), and the cost associated with the treatment (Masson et al., 2016). To counteract
these limitations, many researchers have focused on using current and developmental oxime
reactivators to constantly regenerate inhibited BChE, thus providing a pseudo-catalytic or oxime
assisted catalysis (Katalinic et al., 2016; Busic et al., 2016; Radic et al., 2013; Konickx et al.,
2013; Aurbek et al., 2009). Inhibition of BChE by an OP in the serum followed by reactivation
would allow numerous regenerations of BChE and increase the amount of OP molecules that can
be destroyed, potentially decreasing significant amounts of OP that can reach cardiac and
neuronal AChE. This treatment would be a more cost effective solution and could potentially be
of great value to medical and military personnel.

The current in vitro investigation was designed to determine the BChE reactivation
potential of 8 novel phenoxyalkyl pyridinium oximes (synthesized by the late Dr. Howard
Chambers) and the current oxime platforms 2-pyridinium aldoxime (2-PAM), obidoxime (OBD),
asoxime (HI-6), methoxime (MMB-4), and trimedoxime (TMB-4) in rat, human, and guinea pig
serum after exposure to 8 OP compounds that consisted of nerve agent and insecticidal
chemistries. Rat serum was chosen as a source of BChE as it is a common model used in
toxicity testing and is the model used at Mississippi State University; guinea pig serum was used
as a source of BChE because it is a common model used in nerve agent testing; and human
serum was used for translational purposes and to observe any differences among the tested
animal species. Since Mississippi State University is not allowed to work with the actual nerve
agents, our laboratories have synthesized surrogates for some of the main nerve agents (Meek et
al., 2012). These surrogates inhibit AChE and BChE with the same chemical moieties as the
actual nerve agents but are safer to work with and are thus ideal for initial therapeutic studies.
The nerve agent OPs that were tested consisted of nitrophenyl isopropyl methyl phosphonate
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(NIMP; a sarin surrogate), phthalimidyl isopropyl methylphosphonate (PIMP; a sarin surrogate),
nitrophenyl ethyl methylphosphonate (NEMP; a VX surrogate), nitrophenyl cyclohexyl methyl
phosphonate (NCMP; a cyclosarin surrogate), and diisopropylfluorophosphate (DFP; a
commonly used surrogate for nerve agent testing). In addition to this, two insecticidal OPs:
paraoxon (PXN; metabolite of parathion) and phorate oxon/phorate oxon sulfoxide (PHO,
PHOsox; metabolites of phorate) were also tested.

The data produced demonstrated proof of principle that our novel oximes can reactivate
BChE more effectively than the current oxime therapeutics. The use of different animal models
will contribute to building a library of oxime reactivation data within these species so that, if
necessary, future modifications can be made towards the oximes (structural
modifications/dosages) in addition to identifying differences in reactivation among different
animal species for translational purposes.

Materials and Methods
Materials
Organophosphorus Compounds
Phthalimidyl isopropyl methylphosphonate (PIMP; sarin surrogate), nitrophenyl
isopropyl methylphosphonate (NIMP; sarin surrogate), nitrophenyl ethyl methylphosphonate
(NEMP, VX surrogate), nitrophenyl cyclohexyl methylphosphonate (NCMP; cyclosarin
surrogate) were synthesized in our laboratory and by others (Meek et al., 2012; Ohta et al., 2006;
Fukuto and Metcalf, 1959). Paraoxon and diisopropylfluorophosphate (DFP) were purchased
from Sigma-Aldrich while phorate oxon and phorate oxon sulfoxide were purchased from Chem
Services (see Figure 2-1 for OP structures).
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Oxime Reactivators
Eight novel oximes (OX1, OX9, OX12, OX13, OX15, OX20, OX55, and OX62),
synthesized by the late Dr. Howard Chambers and described in Chambers et al., 2013, were
screened in the in vitro studies (see Figure 2-2 for oxime structures and substitutions). These
oximes contained various substitutions on the phenoxy ring and different alkyl lengths. Oxime
13 was the only oxime tested with a linker chain of 3 alkyl groups, while four oximes (oxime 1,
12, 20 and 55) contained 4 alkyl groups in their linker chains, and three oximes (oxime 9, 15, and
62) contained five alkyl groups in their linker chains. The current oxime therapeutics: 2pyridinium aldoxime (2-PAM), asoxime (HI-6), methoxime (MMB-4), obidoxime (OBD), and
trimedoxime (TMB-4) were purchased from Sigma-Aldrich (see Figure 2-3 for structures of the
current oxime therapeutics).

Tissue
Pooled human serum, Hartley guinea pig serum, and Sprague Dawley rat serum were
used as sources of BChE and were purchased from Innovative Research, Novi, MI.

Methods
Determination of Butyrylcholinesterase Inhibition
A modification of the Ellman method was used to determine BChE activities. A
discontinuous spectrophotometric assay was performed using butyrylthiocholine (BTCh) as the
substrate and 5,5’-dithio-bis(nitrobenzoic acid) (DTNB) as the chromogen (Ellman et al., 1961;
Chambers et al., 1988).
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Pooled rat (Sprague Dawley), human, or guinea pig (Hartley) serum was diluted to
appropriate assay concentrations in 1.5ml test tubes: rat serum was diluted to 0.250ml serum/ml,
guinea pig serum was diluted to 0.050ml serum/ml, and human serum was diluted to 0.025
serum/ml in 0.05M Tris-HCl buffer, pH 7.4 (25˚C). Treatment groups consisted of EtOH
(vehicle control, FC 1%) and various concentrations of OP (in EtOH). The vehicle control group
was used to determine total BChE enzyme activity and to make sure the vehicles themselves did
not cause any inhibition. The various OP concentrations determined the total amount of inhibited
enzyme. Serum was incubated with 10μl ethanol vehicle (FC 1%) or OP (in EtOH) in a shaking
water bath (37°C) for 15 min. Following this, 250μl of each sample was added into 9.75ml of ice
cold 0.05M Tris-HCl buffer. This dilution step removes excess OP that can re-inhibit the
enzyme. After the dilution, 2ml of sample was aliquoted into each of 4 separate glass test tubes.
To correct for non-cholinesterase hydrolysis, 20μl of eserine sulfate (in deionized water, FC
10µM) was added to one of the tubes while the other three were used for BChE measurements.
These samples were placed in a shaking water bath (37°C) for 15 min. After this, 20μl of BTCh
(in EtOH, FC 1mM), was added to all tubes. The samples were incubated for another 15 min.
The reaction was then terminated and color developed by adding 250µl of sodium dodecyl
sulfate (SDS, FC 0.5%)/DTNB (FC 0.6mM) (4:1) mixture to every tube. Absorbance was
measured at 412nm in a Thermo Scientific Biomate 3 spectrophotometer. Concentrations of OP
that inhibited around 85-90% of BChE activity were used.

Calculation of Butyrylcholinesterase Inhibition
Total BChE inhibition was calculated first by determining the average activity of the
three sub- samples and subtracting the eserine value. Total percentage inhibition was calculated
from the absorbances of the total tissue control and total inhibition control (OP alone treatment

34

group) (equation 1). Concentrations of OP that inhibited about 80% of BChE activity were used
for the reactivation experiments.

Equation 1:

(2.1)

Determination of Butyrylcholinesterase Reactivation
Pooled rat (Sprague Dawley), human, or guinea pig (Hartley) serum was diluted to
appropriate assay concentrations in 1.5ml test tubes: rat serum was diluted to 0.250ml serum/ml,
guinea pig serum was diluted to 0.050ml serum/ml, and human serum was diluted to 0.025
serum/ml in 0.05M Tris-HCl buffer, pH 7.4 (25˚C).Treatment groups were: 1) EtOH:DMSO
(vehicle control, 1:1 ratio of EtOH and DMSO, 1%v/v), 2) OP:DMSO (OP alone), 3)
EtOH:Oxime (Oxime alone), 4) OP:Oxime (Oxime+OP). The vehicle control group was used to
determine total BChE enzyme activity and to make sure the vehicles themselves did not cause
any inhibition. The OP alone group determined the total inhibited enzyme, the oxime alone
group determined if the oxime displayed any inhibitory activity towards the enzyme, and the
OP+Oxime group determined the total amount of reactivated enzyme.
Serum was incubated with 10μl ethanol vehicle (FC 1%) or OP (in EtOH) in a shaking
water bath (37°C) for 15 min. Following this, the oxime (FC 100µM) was delivered in a 1:1
solution of dimethyl sulfoxide (DMSO) and ethanol and incubated for 30 min to allow for
reactivation. Following this, 250μl of each sample was added into 9.75ml of ice cold 0.05M TrisHCl buffer. This dilution step removes excess OP that can re-inhibit the enzyme. After the
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dilution, 2ml of sample was aliquoted into each of 4 separate glass test tubes. To correct for noncholinesterase hydrolysis, 20μl of eserine sulfate (in deionized water, FC 10µM) was added to
one of the tubes while the other three were used for BChE measurements. These samples were
placed in a shaking water bath (37°C) for 15 min. After this, 20μl BTCh (in EtOH, FC 1mM)
was added to all tubes. The samples were incubated for another 15 min. The reaction was then
terminated and color developed by adding 250µl of sodium dodecyl sulfate (SDS, FC
0.5%)/DTNB (FC 0.6mM) (4:1) mixture to every tube. Absorbance was measured at 412nm in a
Thermo Scientific Biomate 3 spectrophotometer and three replications were completed for each
oxime.

Calculation of Butyrylcholinesterase Reactivation
To determine the amount of BChE reactivation, the percent of inhibited enzyme was
calculated first. This was accomplished by calculating the average activity of the three subsamples and subtracting the eserine value. After this, total percentage inhibition was calculated
from the absorbances of the total tissue control and total inhibition control (OP alone treatment
group) (equation 2.2).

(2.2)

Next, the inhibition of the oxime control and oxime+OP groups were calculated using
equation 2.3.

(2.3)
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Finally, the total reactivation percentage for each sample was calculated by subtracting
the oxime+OP inhibition from total inhibited enzyme activity which yielded activity of
reactivated enzyme (equation 2.4).

(2.4)

Statistical Analysis
The effect of oximes on percent reactivation was assessed using an analysis of variance
(ANOVA) with PROC MIXED in SAS for Windows v9.4 (SAS Institute, Inc., Cary, NC).
Separate models were run for each inhibitor for human, rat, and guinea pig data. In the case of a
significant oxime effect, an LSMESTIMATE statement was used to compare the means for each
novel oxime to each of the current antidotes (2-PAM, MMB-4, TMB-4, OBD, HI-6). The
SIMULATE option was used to adjust p-values for multiple comparisons for each set of pairwise
comparisons. The distribution of residuals was evaluated to assess if the assumptions of
normality and homoscedasticity had been met. The data were as determined to be normally
distributed by visual assessment of the residual plots. An alpha level of 0.05 was used to
determine statistical significance.

Results
Our novel phenoxyalkyl pyridinium oximes proved to be more efficient BChE
reactivators for several OP compounds for rat inhibited BChE when compared to 2-PAM and the
bis-pyridinium oximes HI-6, TMB-4, MMB-4, and obidoxime (OBD). For PIMP and NEMP inhibited rat BChE, reactivation by our novel oximes ranged from 46-78% for PIMP and 18-88%
for NEMP while 2-PAM and the bis-pyridinium oximes ranged from 31-47% for PIMP and 0-
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8% for NEMP (Figure 2-4). For paraoxon-inhibited rat BChE, our novel oximes displayed
reactivation ranges from 33-95% while 2-PAM and the bis-pyridinium oximes exhibited
reactivation ranges from 4-42% (Figure 2-5). For phorate oxon and phorate oxon sulfoxide
inhibited rat BChE, 2-PAM proved to be the more efficient BChE reactivator. All oximes
displayed greater BChE reactivation towards phorate oxon sulfoxide compared to phorate oxon
(Figure 2-6). For NIMP and DFP-inhibited rat BChE reactivation by our novel oximes ranged
from 38-82% wile 2-PAM and the bis-pyridinium oximes ranged from 0-46% (Figure 2-7).
Reactivation of NCMP-inhibited rat BChE demonstrated poor reactivation by all oximes tested
(Figure 2-8). Novel oxime 15 proved to be the most effective and broad spectrum acting
reactivator for rat OP-inhibited BChE.

In general, all oximes were poor reactivators of OP-inhibited guinea pig BChE with the
exception of PIMP-inhibited BChE (37-69% for the novel oximes and 34-58% for 2-PAM and
the bis-pyridinium oximes, Figure 2-9).

For OP-inhibited human BChE, the only effective novel oxime was oxime 20. Oxime 20
displayed significant reactivation efficacy with PIMP-inhibited BChE (79%, Figure 2-14),
NEMP-inhibited BChE (70%, Figure 2-14), paraoxon-inhibited BChE (66%, Figure 2-15),
phorate oxon-inhibited BChE (83%, Figure 2-16), phorate oxon sulfoxide-inhibited BChE (96%,
Figure 2-16), and NCMP-inhibited BChE (65%, Figure 2-18). 2-PAM and the bis-pyridinium
oximes, in general, were not effective human BChE reactivators for most of the OP compounds
tested. Exceptions were PIMP (reactivation ranges from 36-66%, Figure 2-14), NIMP (72% for
2-PAM, Figure 2-17), phorate oxon (51% for TMB-4, Figure 2-16) and phorate oxon sulfoxide
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(58% for 2-PAM, Figure 2-16). Interestingly, novel oximes 13, 55, and 62 displayed significant
BChE inhibition.

Discussion
Several novel phenoxyalkyl pyridinium oximes, in conjunction with the current oxime in
the United States, 2-PAM, and several bis-pyridinium oximes (TMB-4, MMB-4, HI-6, and
obidoxime) were tested as potential BChE reactivators after inhibition with several OP
compounds which consisted of nerve agent and insecticidal chemistries. The novel oximes varied
in the number of their alkyl linker groups and the substitutions on their phenoxy ring. Oxime 13
was the only oxime tested with a linker chain of 3 alkyl groups, while four oximes (oxime 1, 12,
20 and 55) contained 4 alkyl groups in their linker chain, and three oximes (oxime 9, 15, and 62)
contained five alkyl groups in their linker chain. The oxime position on our novel oximes is in
the para position, which is similar to TMB-4, MMB-4, and obidoxime except for the fact that
these bis-pyridinium oximes have an oxime functional group on each pyridinium ring. 2-PAM
and HI-6 have a single oxime group in the ortho position.

Substantial species differences in BChE reactivation were observed by all of the oximes
tested. In general, all oximes showed higher BChE reactivation for all compounds tested towards
OP-inhibited rat BChE. The reactivation efficacy proceeded from rat>human>guinea pig. The
only notable difference was novel oxime 20, which showed impressive, broad spectrum
reactivation towards 6 of the 8 OP compounds tested for human BChE, reaching greater than
70% reactivation for sarin and VX surrogates, and the phorate metabolites (phorate oxon and
phorate oxon sulfoxide). Interestingly, the only OP compound which showed consistent,
appreciable reactivation for all oximes in all species was PIMP-inhibited BChE, one of the sarin
surrogates tested. The other sarin surrogate, NIMP, and DFP, were not reactivated as effectively
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as PIMP-inhibited BChE and, in fact, DFP, in addition to NCMP, the cyclosarin surrogate,
proved to be one of the more difficult OPs to reactivate in all species tested. NIMP displayed
similar reactivation efficacy in rat compared to PIMP but was different in human and guinea pig.
This is an interesting observation since NIMP and PIMP should theoretically display similar
reactivation efficacies since the phosphorylated product on the enzyme complex is the same
compound: isopropyl methylphosphonate. A similar pattern was observed with paraoxon,
phorate oxon, and phorate oxon sulfoxide. All three of these compounds become diethyl
phosphates once their respective leaving group departs. Most of the oximes displayed higher
reactivation efficacy towards paraoxon-inhibited BChE. Interestingly, the two phorate
metabolites, phorate oxon and phorate oxon sulfoxide, produced different reactivation results as
well, with an increase of reactivation seen with phorate oxon sulfoxide when compared to
phorate oxon.

Even though several of these OP compounds leave the enzyme phosphorylated with
similar chemical moieties, differences in their reactivation could be due to their different leaving
groups. The leaving group plays an important part in orienting the phosphoryl group in the active
site once the OP is bound in the enzyme and has been demonstrated to affect the inhibition,
aging, and spontaneous reactivation rates of OP-inhibited AChE (Carr and Chambers, 1996).
These differences in orientation could play an important role in positioning the OP within the
active site that may orient the R groups on the phosphoryl moiety in a position that could cause
steric hindrance and potentially reduce oxime entrance into the active site, especially with
compounds that have large R groups. Indeed, the compounds with the larger side chains, NCMP
and DFP, proved to be the most challenging OPs to reactivate in all species tested for most of the
oximes tested. Interestingly, this was not the case for oxime 20 reactivation of NCMP-inhibited
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human BChE. Therefore, this assumption cannot be generalized across all species and for all
OPs. It is more likely that the combination of the structure of the phosphoryl moieties and the
size/species differences in the enzyme structure are the important determinants of oxime induced
reactivation. Research suggests that rat and human BChE exhibit high similarities in their amino
acid sequence, but differences between rat BChE and human BChE exist between their inhibition
by OPs, reactivation by oximes, and size of their active site (Boeck et al., 2002). The smaller
active site in rat BChE could explain the low reactivation seen for all oximes with the OPs that
have larger R groups, such as the cyclohexyl found in NCMP and the diisopropyl found in DFP,
since these bulky side chains could block the active site.

Conclusion
The results indicated that several of our novel phenoxyalkyl pyridinium oximes are more
effective BChE reactivators than the current oxime therapeutics. Novel oxime 15 was the most
effective oxime for rat OP-inhibited BChE while novel oxime 20 was the most effective oxime
for human OP-inhibited BChE. Novel oxime 20 did show sufficient reactivation efficacy for OPinhibited rat BChE. This oxime has emerged as one of our lead in vivo oximes. Research in our
laboratory has shown increased survivability after exposure to sarin and VX surrogates compared
to 2-PAM (Chambers et al., 2016). It is plausible that oxime induced reactivation of OP inhibited
BChE in the circulation could be detoxifying significant amounts of OP, thus contributing to
increased survival rates.

Both of these oximes exhibited broad spectrum capabilities for nerve agent and
insecticidal chemistries. This is promising since it is highly desirable for an oxime to have high
efficacy for a scavenging enzyme when it is inhibited by different OPs. This greatly increases the
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chances of additional scavenging of OP molecules regardless of the OP and could be used in
conjunction with more powerful AChE reactivators to allow for additional protection.

While these experiments demonstrated proof of principle that they can reactivate OP
inhibited BChE, several questions remain: such as how long does it take to achieve >50% BChE
reactivation, and how efficient are these oximes for OP-inhibited BChE? It is likely the assay
reactivation time of 30 minutes used in the present screening assays is too long to be considered
an effective BChE reactivator. Reactivation needs to happen quickly as the OP will leave the
circulation and enter into the target tissues very rapidly. It is also unclear how much BChE
reactivation is needed to detoxify enough OP molecules to reduce toxicity. Nevertheless, these
experiments demonstrate promising results that require further investigation.
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Figure 2.1

Structure of nerve agents, nerve agent surrogates, and OP insecticidal oxons
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Oxime 1

n= 4 R= 4-Cl-

Oxime 9

n= 5 R= 4-CH3-O-

Oxime 12

n= 4 R= 4-CH3CH2C(:O)-

Oxime 13

n= 3 R= 3-CH=CHCH=CH-4

Oxime 15

n= 5 R=4-CH3CH2C(:O)-

Oxime 20

n= 4 R= 4-Ph-CH2-O-

Oxime 55

n= 4 R= 4(CH3)3CCH2C(CH3)2

Oxime 62

n= 5 R= 4-(CH3)3CCH2C(CH3)2

Figure 2.2

Structure of novel phenoxyalkyl pyridinium oximes (US patent 9,277,937)
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Figure 2.3

Chemical structures of currently used pyridinium and bis-pyridinium oxime
reactivators. Retrieved from Mercey et al., 2012.
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Figure 2.4

Rat serum BChE reactivation after inhibition by PIMP and NEMP. Data were
analyzed by ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05 compared
to 2-PAM.
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Figure 2.5

Rat serum BChE reactivation after inhibition by paraoxon. Data were analyzed by
ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05 compared to 2-PAM
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Rat serum BChE reactivation after inhibition by phorate oxon and phorate oxon
sulfoxide. Data were analyzed by ANOVA and are expressed as mean ± SEM.
N=3
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Rat serum BChE reactivation after inhibition by NIMP and DFP. Data were
analyzed by ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05 compared
to 2-PAM
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Figure 2.8

Rat serum BChE reactivation after inhibition by NCMP. Data were analyzed by
ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05 compared to 2-PAM
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Guinea pig serum BChE reactivation after inhibition by PIMP and NEMP. Data
were analyzed by ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05
compared to 2-PAM
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Figure 2.10

Guinea pig serum BChE reactivation after inhibition by paraoxon. Data were
analyzed by ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05 compared
to 2-PAM
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Figure 2.11

Guinea pig serum BChE reactivation after inhibition by phorate oxon and phorate
oxon sulfoxide. Data were analyzed by ANOVA and are expressed as mean ±
SEM. N=3 p*≤0.05 compared to 2-PAM
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Figure 2.12

Guinea pig serum BChE reactivation after inhibition by NIMP and DFP. Data
were analyzed by ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05
compared to 2-PAM
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Figure 2.13

Guinea pig serum BChE reactivation after inhibition by NCMP. Data were
analyzed by ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05 compared
to 2-PAM
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Figure 2.14

Human serum BChE reactivation after inhibition by PIMP and NEMP. Data were
analyzed by ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05 compared
to 2-PAM
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Figure 2.15

Human serum BChE reactivation after inhibition by paraoxon. Data were
analyzed by ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05 compared
to 2-PAM
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Figure 2.16

Human serum BChE reactivation after inhibition by phorate oxon and phorate
oxon sulfoxide. Data were analyzed by ANOVA and are expressed as mean ±
SEM. N=3 p*≤0.05 compared to 2-PAM
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Human serum BChE reactivation after inhibition by NIMP and DFP. Data were
analyzed by ANOVA and are expressed as mean ± SEM. N=3
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Human serum BChE reactivation after inhibition by NCMP. Data were analyzed
by ANOVA and are expressed as mean ± SEM. N=3 p*≤0.05 compared to 2-PAM
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CHAPTER III
IN VITRO REACTIVATION KINETICS OF RAT AND HUMAN
SERUM BUTYRYLCHOLINESTERASE AND ELECTRIC EEL
ACETYLCHOLINESTERASE BY NOVEL
PHENOXYALKYL PYRIDINIUM OXIMES
AFTER INHIBITION BY A
SARINSURROGATE
AND PARAOXON
Introduction
Organophosphates (OPs) are potent inhibitors of acetylcholinesterase (AChE) and
butyrylcholinesterase (BChE). Inhibition of AChE leads to a buildup of acetylcholine (Ach) and
a persistent stimulation of the nicotinic and muscarinic cholinergic receptors throughout the
central and peripheral nervous systems. A cholinergic crisis ensues resulting in increased
mucosal secretions, bronchoconstriction, cardiac distress, and excitotoxic seizures. Death at
lethal exposure levels happens quickly from respiratory failure if treatment is not quickly
administered.

The main treatment for OPs consists of atropine sulfate and pralidoxime (2-PAM).
Atropine sulfate blocks muscarinic receptor subtypes, attenuating autonomic nervous system
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hyperactivity. Oximes such as 2-PAM are used to remove the phosphoryl group from the
inhibited enzyme, thereby attenuating the over-stimulation of both the nicotinic and muscarinic
receptors and allowing the body to return to homeostasis (Hobbiger and Sadler,1959). This
process is called reactivation and is the primary method of oxime effectiveness. Oximes vary in
their ability at reactivating OP-inhibited AChE and a broad spectrum acting reactivator has yet to
be found.

In contrast to AChE, inhibition of serum and tissue BChE does not lead to toxic effects.
Serum BChE serves as an endogenous scavenger of circulating toxic esters, including OPs, thus
potentially reducing the amount of OP that can reach AChE and cause toxicity (Lockridge,
2015). Unfortunately the low amount of BChE in human serum (50nM) is too low to protect
against a high level OP exposure (Nachon et al., 2013). Administration of exogenous human
BChE has afforded protection in animal models to 5.5 x LD50 of soman and 8x LD50 of VX
(Saxena et al., 2011). However, because this reaction destroys both enzyme and OP in a 1:1
stoichiometric fashion, it has been determined that the doses required to confer protection are not
economically feasible (Nachon et al., 2013). Research has focused on large scale production of
BChE and determining if animal and recombinant sources of BChE are effective alternatives
(Geyer et al., 2010; Nachon et al., 2002; Brazzolotto et al., 2012; Li et al., 2010; Huang et al.,
2007; Geyer et al., 2010; Baldassarre et al., 2009). While some promising individual results have
come forth, affordable doses and effective production solutions have yet to be found.

To counter these deficiencies, using oxime reactivators to constantly regenerate OP
inhibited BChE has been an emerging technique. Inhibition of BChE in the circulation followed
by an oxime could potentially allow for numerous regenerations of inhibited enzyme. This could
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greatly increase the number of OP molecules that could be destroyed. If effective, this could
reduce the amount of enzyme needed (and thus the costs) associated with exogenous BChE
treatment. Unfortunately, the current oxime platforms were originally designed to reactivate
human AChE. Research suggests that current and developmental oxime platforms are not
effective BChE reactivators (Aurbek et al., 2009; Horn et al., 2015; Radic et al., 2013).

The reactivation reaction scheme of OP inhibited AChE or BChE proceeds in a two step
reaction (see Scheme 1 for reactivation reaction). The oxime first approaches the inhibited
enzyme and binds to it, forming a reversible OP-oxime-enzyme Michaelis-Menten type complex.
The second step is the removal of the OP adduct from the enzyme (Worek et al., 2013).
Performing reactivation kinetics calculations produces rate constants (KD, kr, kr2) that
quantitatively detail the effectiveness of an oxime’s ability to reactivate OP inhibited enzyme.
The equilibrium constant KD represents the dissociation constant, which is inversely proportional
to the affinity of the oxime towards inhibited enzyme. The first order rate constant kr details the
intrinsic reactivity of the oxime, which is the ability of the oxime to remove the OP from the
enzyme. The second order rate constant, kr2, is determined by the ratio of kr and KD and
determines the overall efficiency of the reactivation process (Worek et al., 2007).

Scheme 3.1 Schematic representation of reactivation of OP inhibited enzyme by an oxime
reactivator where [E-P] is the inhibited enzyme, [OX] is the oxime reactivator, [EPOX] is the
reversible Michaelis-Menten phosphonylenzyme-oxime complex and [P-OX][E] is
phosphonylated oxime and free enzyme.
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The current in vitro investigation was designed to determine the BChE reactivation rate
constants of two novel phenoxyalkyl pyridinium oximes, oxime 15 (OX15) and oxime 20
(OX20) (synthesized by the late Dr. Howard Chambers), and the currently FDA approved oxime
2-PAM in rat and human serum after inhibition by the sarin surrogate NIMP and the insecticidal
metabolite paraoxon. In addition to this, the reactivation rate constants for these two oximes and
2-PAM were determined in electric eel AChE after inhibition by NIMP and paraoxon to
determine if these novel oximes were better reactivators of AChE or BChE. Since Mississippi
State University is not authorized to work with the actual nerve agents, our laboratories have
synthesized surrogates for some of the main nerve agents (Meek et al., 2012; Ohta et al., 2006).
These surrogates inhibit AChE and BChE with the same chemical moieties as the actual nerve
agents but are safer to work with and are thus ideal for initial therapeutic studies. Because
significant animal differences in oxime reactivation on AChE compared to human AChE are
well documented (de Jong et al., 1984; Worek et al., 2002; Luo et al., 2007), this study used
multiple test species.

Materials and Methods
Materials
Organophosphorus Compounds
Nitrophenyl isopropyl methylphosphonate (NIMP; sarin surrogate) was synthesized in
our laboratory (Meek et al., 2012) and originally described by (Ohta et al., 2006). Paraoxon
(>98%) was synthesized by the late Dr. Howard Chambers. Purity was determined by Nuclear
Magnetic Resonance (NMR) at Mississippi State University, Department of Chemistry.
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Oxime Reactivators
Two novel oximes (OX15, OX20), originally described in Chambers et al. (2013), were
demonstrated to be the most effective BChE reactivators from chapter II and therefore
progressed to chapter III for oxime reactivation kinetic determinations. 2-PAM was used as a
comparison and it was purchased from Sigma-Aldrich (St. Louis, MO).

Tissue
Pooled human serum and Sprague Dawley rat serum were used as sources of BChE and
were purchased from Innovative Research, Novi, MI. Purified electric eel AChE was purchased
from Sigma-Aldrich (St. Louis, MO). Electric eel was chosen as source of enzyme as it is an
affordable and active enzyme that our laboratory has previous experience with.

Methods
Determination of Butyrylcholinesterase Inhibition
Pooled rat or human serum was diluted to appropriate assay concentrations in two 1.5ml
test tubes. Rat serum was diluted to 0.250ml serum/ml and human serum was diluted to 0.025ml
serum/ml in 0.05M Tris-HCl buffer, pH 7.4 (25˚C). Following this, to one tube was added 10µl
of ethanol vehicle while to the other one 10µl of various concentrations of either NIMP (in
EtOH) or paraoxon (in EtOH) was added. Following this, a 40 fold dilution was completed by
the addition of 250μl of sample into 9.750ml of ice cold buffer to bring total volume to 10ml.
Following this, 50μl of a mixture of butyrylthiocholine (BTCh in EtOH, FC 4mM)/5,5’dithio bis(2-nitrobenzoic acid)(DTNB, FC 1.2mM) was added to each well of a 96 well plate.
The reaction was initiated by the addition of 198μl of uninhibited tissue or inhibited tissue. The
uninhibited tissue samples were used to observe total enzyme activity and the inhibited tissue

68

samples were used to observe total inhibited enzyme activity. After these additions, the 96 well
plate was immediately placed in a Biotek Plate Reader, at 37°C, where absorbance readings
(412nm) were recorded every 26 seconds for 30 minutes. Linear regression was performed on
the control (EtOH vehicle) and on each individual OP concentration to determine the slope.
Percent inhibition of control (EtOH vehicle) was calculated for each individual OP
concentration. Concentrations of OP that inhibited >90-95% were used for the reactivation
experiments.

Determination of Butyrylcholinesterase Reactivation
Pooled rat or human serum was diluted to appropriate assay concentrations in two 1.5ml
test tubes. Rat serum was diluted to 0.250ml serum/ml and human serum was diluted to 0.025ml
serum/ml in 0.05M Tris-HCl buffer, pH 7.4 (25˚C). Following this, to one tube was added 10µl
of ethanol vehicle while to the other one 10µl of either NIMP (in EtOH) or paraoxon (in EtOH)
was added. After 15 minutes of incubation in a shaking water bath at 37°C, samples underwent
fast ultrafiltration to remove excess OP.
Briefly, for each sample (vehicle and OP sample) two aliquots of 500μl were delivered
into two separate Amicon Ultra Centrifugal Filter Device tubes (Molecular Weight Cutoff
10,000 kDa) for a total of four tubes. These were placed in an Eppendorf microcentrifuge and
spun at 14,000g for 5 minutes at 4°C. Proteins that were above 10,000 kDa were not filtered and
were collected in the filter device tube, including the OP-BChE complex. Compounds that were
below 10,000 kDa passed through the column into the filtrate collection tube, including the
unbound OP. Three x five minute spins were completed. After each spin, the samples were
brought to 0.5ml by the addition of 434μl buffer. After the third spin, the filter device was placed
upside down into a new, clean centrifuge tube and spun for 2 minutes at 1,000g so that the
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concentrated sample could be collected. The appropriate samples were combined and brought to
0.750ml by addition of 350μl buffer. Following this, a 40 fold dilution was completed by the
addition of 250μl of sample into 9.750ml of ice cold buffer to bring total volume to 10ml.
Following this, 50μl of a mixture of butyrylthiocholine (BTCh in EtOH, FC 4mM)/5,5’dithio bis(2-nitrobenzoic acid)(DTNB, FC 1.2mM) was added to each well of a 96 well plate.
After this, 2μl of various concentrations of oxime (OX15, OX20, or 2-PAM) ranging from final
concentrations of 1μM to 75μM were added to wells which were to contain either inhibited or
uninhibited enzyme. Vehicle controls (ethanol and ethanol:DMSO) were then added (2μl) to
make sure there was no vehicle induced inhibition of the enzyme. The reaction was initiated by
the addition of 198μl of uninhibited tissue, inhibited tissue, or Tris HCl buffer 0.05M. The
uninhibited tissue samples were used to observe total enzyme activity. The inhibited tissue
samples were used to observe total inhibited enzyme activity and reactivated enzyme activity.
The addition of buffer was used to observe oxime induced hydrolysis of substrate without the
presence of enzyme. After these additions, the 96 well plate was immediately placed in a Biotek
Plate Reader, at 37°C, where absorbance readings (412nm) were recorded every 26 seconds for
30 minutes. All conditions were performed in duplicate.

AChE Activity Determination
Purified electric eel was used as source of acetylcholinesterase (AChE). Activities were
monitored in a similar fashion as BChE as described previously. The only difference was that the
substrate used was acetylthiocholine (ATCh in EtOH, FC 4mM). DTNB (1.2mM) was used as
the chromogen in 0.05M Tris HCl buffer (pH 7.4, 25°C).
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Inhibition of AChE by Organophosphates
Electric eel AChE (5U) was incubated at 37°C with either ethanol/DMSO (1:1) vehicle,
paraoxon or NIMP for 15 minutes in a shaking water bath to achieve >90% inhibition and was
determined in a similar fashion as BChE as described previously.

AChE Reactivation
Vehicle and paraoxon-inhibited or NIMP-inhibited AChE were diluted 200 fold into 8ml
of 0.05M Tris HCl buffer (pH 7.4, 25°C) and 198µl were aliquoted into wells of a 96 well plate
containing a mixture of 4mM ATCh, 1.2mM DTNB, and eight different oxime concentrations
(ranging from FC 1µM-150µM for OX15 and 1µM-75µM for OX20 and 2-PAM) to achieve a
final volume of 250µl per well and a FC enzyme activity of 0.02U. ATCh hydrolysis was
continuously monitored by using a BioTek Synergy HT Multi-Mode Microplate Reader where
absorbance readings (412nm) were recorded every 26 seconds for 30minutes. Sample assays
were performed in duplicate. Oximes were corrected for oxime-induced hydrolysis of the
substrate.

Data Analysis
For wells that contained oximes, background activity resulting from oxime induced
hydrolysis of the substrate without enzyme was subtracted to determine total enzyme activity.
Linear regression on each individual oxime concentration’s control was used to determine the
slope. Non linear regression was then performed using equation 3.1 on the absorbance vs time
reactivation kinetic plots (see Figure 3-1 for representative example) to determine the pseudofirst order rate constant kobs (Moyer et al., 2018; Luo et al., 2007; Worek et al., 2004). Each
oxime concentration that demonstrated reactivation was compared to its own oxime control for a
more accurate analysis of reactivation
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(3.1)

Where A is absorbance, Y0 is absorbance at time zero, V0 is the maximum velocity (total
activity of uninhibited enzyme) at time zero, t is time, and kobs is the pseudo first order rate
constant.

Plotting the kobs vs oxime concentration and fitting the data to a hyperbola (Equation 3.2)
allowed the calculation of the first order reactivation rate constant kr, which reflects the oxime’s
ability to remove the OP from the inhibited enzyme and the dissociation constant KD, which is
inversely proportional to the oxime’s affinity for the phosphorylated enzyme. The second order
reactivation rate constant kr2, which details the efficiency of the reactivation process, was
calculated from equation 3.3 by taking the ratio of kr and KD (Moyer et al., 2018; Luo et al.,
2007; Worek et al., 2004).

kobs=

(3.2)

=

(3.3)

Results
Both novel oximes proved to be efficient reactivators of NIMP- and paraoxon-inhibited
electric eel AChE, indicating a high reactivity and reactivation potency (Figure 3-2-Figure 3-5).
OX15 was the most effective oxime for paraoxon-inhibited AChE with a kr2 of 3.40mM-1min-1
followed by OX20 with a kr2 of 2.76mM-1min-1. Novel OX20 was a more effective oxime for
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NIMP-inhibited AChE with a kr2 of 2.14mM-1min-1. Both oximes were more efficient
reactivators than 2-PAM at reactivating OP inhibited electric eel AChE (Table 1 and Table 2).
For paraoxon-inhibited human serum BChE, reactivation rate constants could not be
determined for 2-PAM or OX15 (Table 3). This was because these oximes displayed slow rates
of reactivation. When oximolysis was subtracted from these values, a negative number was
produced which prevented the calculation of the rate constants. OX20 indicated a modest
reactivity towards paraoxon-inhibited human serum BChE with a kr2 of 0.593mM-1min-1 (Table
3). For NIMP-inhibited human serum BChE, novel OX20 indicated impressive reactivation
efficiency with a kr2 of 9.78mM-1min-1 followed by oxime 15, with a kr2 4.36mM-1min-1. Both
oximes were more effective reactivators of NIMP-inhibited human serum BChE than 2-PAM
(Table 4).
For OP-inhibited rat BChE, all oximes displayed low intrinsic reactivation potency (kr)
and high affinity for the inhibited enzyme (KD) which produced higher kr2 values (Table 5 and
Table 6). Novel OX15 proved to be the most effective reactivator of paraoxon-inhibited rat
BChE with a second order rate constant of 142.73mM-1min-1 while OX20 was the most effective
reactivator for NIMP-inhibited rat serum BChE with a second order rate constant of 1.02mM1

min-1. Rate constants for novel OX15 could not be determined for NIMP-inhibited rat serum

BChE but OX15 was an effective reactivator of paraoxon-inhibited rat BChE, with a second
order rate constant of 21.15mM-1min-1. Both novel oximes were more effective reactivators than
2-PAM at reactivating OP inhibited rat BChE.

Discussion
Reactivation rate constants for OP inhibited electric eel AChE and rat and human serum
BChE were determined for two novel phenoxyalkyl pyridinium oximes, OX15 and OX20, and 2-
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PAM. Tested OPs consisted of the insecticidal metabolite paraoxon and the sarin surrogate
NIMP. Results indicated high intrinsic oxime reactivity for NIMP- and paraoxon-inhibited
electric eel AChE for OX15 and OX20. Both oximes displayed similar reactivity with paraoxoninhibited electric eel AChE, with a kr of 0.2min-1 for both oximes, and NIMP-inhibited electric
eel AChE with a kr of 0.17min-1. 2-PAM also showed high reactivity with paraoxon-inhibited
electric eel AChE with a kr of 0.19min-1, but was not better than OX15 or OX20. 2-PAM
displayed poor reactivity towards NIMP-inhibited electric eel AChE. Dissociation constants,
reflected by KD, for the two novel oximes were less than for 2-PAM indicating higher affinity
and reactivity towards paraoxon- and NIMP-inhibited enzyme. These values were around
100µM for both OP compounds and 2-PAM. The second order rate constants for 2-PAM for
NIMP (sarin surrogate) and paraoxon were close to that of the second order rate constants of
sarin and paraoxon inhibited human AChE (Worek et al., 2002; Worek et al., 2004; Worek et al.,
2011), indicating that electric eel AChE is a good model for human AChE.
For rat and human BChE rate constants, OX20 was the only oxime that showed sufficient
reactivity towards NIMP-inhibited human serum BChE, with a kr of 0.1min-1 and an extremely
high affinity towards the NIMP-inhibited enzyme (less than 20µM). All oximes displayed high
affinity (less than 10µM) but low reactivity (kr of less than 0.015min-1) towards paraoxoninhibited rat BChE.
According to Worek et al. (2011), a minimum requirement for an effective oxime
reactivator is a kr of >0.1min-1 and a KD of 100µM or lower. Both novel oximes met these
requirements for paraoxon- and NIMP-inhibited electric eel AChE while OX20 also met these
requirements for NIMP-inhibited human serum BChE, indicating strong reactivity towards
structurally different OPs and different enzymes. The second order rate constant, kr2, which
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details the overall efficiency of the reactivation process, was higher for our novel oximes than 2PAM for all compounds and enzymes tested.
The oximes displayed lower intrinsic reactivity (kr) towards OP-inhibited BChE than for
OP-inhibited AChE. This could be due to the fact that the larger active site in BChE compared to
AChE could prevent proper orientation of the oxime towards the phosphylated product (Vellom
et al., 1993). However, this poor reactivity was offset by a very high binding affinity, especially
for OP-inhibited rat BChE. Saturation was reached very quickly with the oximes tested for OPinhibited rat BChE, which could be explained by the very high binding affinity. The smaller
active site in rat BChE compared to human BChE has been noted (Boeck et al., 2002), and this
could be an important determinant of oxime binding for these small, lipophilic, novel oximes.

Conclusion
The results indicate that our oximes are more effective reactivators of electric eel AChE
and human and rat serum BChE for paraoxon- and NIMP-inhibited enzyme than the current
oxime therapeutic 2-PAM. These novel phenoxyalkyl pyridinium oximes have added lipophilic
moieties and were synthesized to improve the amount of oxime that can enter into brain and
protect against OP-induced brain damage. Indeed, data from our lab has shown increased
survival rates and neural protection in rats after exposure to a sarin surrogate and paraoxon when
compared to 2-PAM (Chambers et al., 2016; Dail et al., 2018). A possible reasoning into this
increased survivability and brain protection could be an increase in the detoxication of OP
molecules in the circulation by oxime assisted reactivation of OP-inhibited serum BChE. Oxime
induced reactivation of OP inhibited BChE would theoretically allow fewer OP molecules to
reach critical AChE target areas such as the brain. Additionally, based on the electric eel AChE
data, these oximes do possess the capability to effectively reactivate AChE. Reactivation of
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AChE and BChE could provide a dual therapeutic effect. Perhaps not too surprisingly, OX20 has
emerged as one of our lead in vivo oximes. Data represented here has shown that OX20 is an
effective OP-inhibited AChE and BChE reactivator of a sarin surrogate and paraoxon.
Additional studies into OP inhibited human AChE and more structurally diverse OPs are
needed to assess the true effectiveness of these novel oximes. A critical need exists to develop
oximes that are broad spectrum and neuroprotective and these data suggest that our novel
phenoxyalkyl pyridinium oximes are showing promise as broad spectrum acting and neural
protecting oxime reactivators.
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Table 3.1

Reactivation rate constants kr and kr2, and KD for 2-PAM and novel oximes 15 and
20 for paraoxon inhibited electric eel AChE.

Oxime
KD(µM)
kr (min-1)
2-PAM
95±16
0.194±0.038
Oxime 15
70±59
0.222±0.023
Oxime 20
84±34
0.220±0.163
Data are represented as mean± SD (n=2 observations).

Table 3.2

Reactivation rate constants kr and kr2, and KD for 2-PAM and novel oximes 15 and
20 for NIMP inhibited electric eel AChE.

Oxime
KD(µM)
kr (min-1)
2-PAM
126±148
0.051±0.013
Oxime 15
108±34
0.171±0.011
Oxime 20
79±26
0.170±0.054
Data are represented as mean± SD (n=2 observations).

Table 3.3

kr2 (mM-1min-1)
1.09±1.16
1.63±0.40
2.14±0.04

Reactivation rate constants kr, kr2, and KD for 2-PAM and novel oximes 15 and 20
for paraoxon inhibited human serum BChE.

Oxime
KD(µM)
kr (min-1)
2-PAM
Ø
Ø
Oxime 15
Ø
Ø
Oxime 20
84±20
0.048±0.012
Data are represented as mean± SD (n=2-3 observations).

Table 3.4

kr2 (mM-1min-1)
2.09±0.76
3.40±0.81
2.76±0.81

kr2 (mM-1min-1)
Ø
Ø
0.59±0.05

Reactivation rate constants kr, kr2, and KD for 2-PAM and novel oximes 15 and 20
for NIMP inhibited human serum BChE.

Oxime
KD(µM)
kr (min-1)
2-PAM
13±15
0.008±0.002
Oxime 15
60±58
0.078±0.029
Oxime 20
18±18
0.100±0.012
Data are represented as mean± SD (n=2-3 observations).
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kr2 (mM-1min-1)
1.23±1.21
4.36±6.17
9.78±3.34

Table 3.5

Reactivation rate constants kr, kr2, and KD for 2-PAM and novel oximes 15 and 20
for paraoxon inhibited rat serum BChE.

Oxime
KD(µM)
kr (min-1)
2-PAM
8.14±11
0.010±0.001
Oxime 15
0.52±0.67
0.011±0.005
Oxime 20
0.42±0.22
0.012±0.008
Data are represented as mean± SD (n=2-3 observations).

Table 3.6

kr2 (mM-1min-1)
58.51±81.80
142.73±191
38.74±39.97

Reactivation rate constants kr and kr2, and KD for 2-PAM and novel oximes 15 and
20 for NIMP inhibited rat serum BChE.

Oxime
KD(µM)
kr (min-1)
2-PAM
278±295
0.060±0.058
Oxime 15
Ø
Ø
Oxime 20
24±8
0.024±0.005
Data are represented as mean± SD (n=2-3 observations).

78

kr2 (mM-1min-1)
0.24±0.04
Ø
1.02±0.29
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Figure 3.1

Representative absorbance vs time plot of the reactivation kinetics of NIMP
inhibited electric eel AChE by OX20 (1µM-75µM).
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Plot of kobs for NIMP inhibited electric eel AChE reactivated by various
concentrations of OX20. kobs vs [OX20] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.98
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Figure 3.3

Plot of kobs for paraoxon inhibited electric eel AChE reactivated by various
concentrations of OX20. kobs vs [OX20] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.97
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Figure 3.4

Plot of kobs for NIMP inhibited electric eel AChE reactivated by various
concentrations of OX15. kobs vs [OX15] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.99
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Figure 3.5

Plot of kobs for paraoxon inhibited electric eel AChE reactivated by various
concentrations of OX15. kobs vs [OX15] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.95
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Figure 3.6

Plot of kobs for NIMP inhibited electric eel AChE reactivated by various
concentrations of 2PAM. kobs vs [2PAM] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.91
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Figure 3.7

Plot of kobs for paraoxon inhibited electric eel AChE reactivated by various
concentrations of 2PAM. kobs vs [2PAM] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.98
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Figure 3.8

Plot of kobs for NIMP inhibited rat serum BChE reactivated by various
concentrations of OX20. kobs vs [OX20] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.93
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Figure 3.9

Plot of kobs for paraoxon inhibited rat serum BChE reactivated by various
concentrations of OX20. kobs vs [OX20] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.93
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Figure 3.10

Plot of kobs for paraoxon inhibited rat serum BChE reactivated by various
concentrations of OX15. kobs vs [OX15] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.95
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Plot of kobs for NIMP inhibited rat serum BChE reactivated by various
concentrations of 2PAM. kobs vs [2PAM] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.90
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Plot of kobs for paraoxon inhibited rat serum BChE reactivated by various
concentrations of 2PAM. kobs vs [2PAM] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.65
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Plot of kobs for NIMP inhibited human serum BChE reactivated by various
concentrations of OX15. kobs vs [OX15] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.99
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Plot of kobs for NIMP inhibited human serum BChE reactivated by various
concentrations of OX20. kobs vs [OX20] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.97
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Plot of kobs for paraoxon inhibited human serum BChE reactivated by various
concentrations of OX20. kobs vs [OX20] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.99
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Plot of kobs for NIMP inhibited human serum BChE reactivated by various
concentrations of 2PAM. kobs vs [2PAM] allowed the determination of the rate
constant kr and affinity constant KD. R2 of 0.90
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CHAPTER IV
INTRANASAL DELIVERY OF OXIMES FOLLOWING EXPOSURE TO A SARIN
SURROGATE
Introduction
Organophosphorus compounds (OPs) potently inhibit the serine hydrolase
acetylcholinesterase (AChE). Its inhibition rapidly leads to an accumulation of the excitatory
neurotransmitter acetylcholine (Ach) in the peripheral and central nervous systems. This increase
in Ach leads to a persistent stimulation of nicotinic and muscarinic receptors which, as a
consequence to high dosage exposures, can lead to respiratory distress, excitotoxic seizures, and
death to the victim if treatment is not quickly administered. Treatment strategies consist of the
antimuscarinic drug atropine sulfate, an oxime reactivator such as 2-PAM to remove the
phosphoryl moiety from the inhibited enzyme, and an anticonvulsant such as diazepam to control
seizures. Even if the victim survives, long term brain damage can still occur because of
prolonged seizures if treatment is not quickly administered (Aroniadou-Anderjaska et al., 2016).
Research shows that several years after the nerve agent attack in the Tokyo subway system by
the terrorist group Aum Shinrikyo (AUM), victims showed significant atrophy in multiple brain
regions (Yamasue et al., 2007; Yamasue et al., 2003; Rogers et al., 2009).

The proposed mechanism of seizure onset and maintenance in experimental animal
models following organophosphate challenge has been suggested to consist of three distinct
phases: the cholinergic phase (which lasts from the time of exposure to about 5 minutes after
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seizure onset), the mixed cholinergic phase (which begins after 5 minutes and can last until 40
minutes), and the noncholinergic phase which begins around 40 minutes (McDonough and Shih,
1997). The initial cholinergic phase results from the OP induced inhibition of AChE and its
subsequent decrease in its activity. This inhibition causes a persistent increase of Ach levels in
the brain (Flynn et al., 1986; Flynn et al., 1987; Fosbraey et al., 1990) which is an important
initiator of seizure activity because the elevation of Ach levels causes an increase in excitatory
activity of the brain that can spread and disrupt other neurotransmitter systems (McDonough and
Shih, 1997). In fact, within the first few minutes of OP exposure and seizure onset, cholinergic
activity is the only neurotransmitter system that is notably perturbed (McDonough and Shih,
1997). The mixed cholinergic and noncholinergic phases begin to occur 5-40 minutes after
seizure onset and consist of other neurotransmitter systems and secondary messenger systems
that are increased such as glutamate and calcium (Ca++), respectively, which have the potential to
be neurotoxic, and the decrease in activity of the inhibitory neurotransmitter GABA
(McDonough and Shih, 1997).

In a high dose exposure of OPs, brain regions that display high AChE inhibition, such as
the basolateral nucleus of the amygdala and the hippocampus, show significant neuropathology
and brain damage from seizures induced by OPs (Aroniadou-Anderjaska et al., 2016). These
regions play important roles in memory, emotion, and cognitive function, and impairment of
these areas leads to neurological and behavioral abnormalities. The current treatment strategy for
attenuating seizures is administration of diazepam, a benzodiazepine. However, the use of
diazepam has produced mixed results at attenuating neuropathology and brain damage even if
seizures are stopped, and it poses health risks if repeated administrations are needed (Apland et
al., 2014; Goodkin et al., 2008; Naylor, 2010).
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Therefore, being able to rapidly attenuate AChE inhibition by oxime reactivator treatment
is paramount to preventing the cascade of secondary events that can cause persistent seizures and
brain damage. Unfortunately, the currently approved oxime reactivator therapeutics only act in
the peripheral nervous system, so the central nervous system AChE remains inhibited (Gallagher
et al., 2016; Kalasz et al., 2014; Worek and Thiermann, 2013; Lorke et al., 2008; Sakurada et al.,
2003; Clement, 1979). A critical research goal for scientists has been to develop an oxime that
has the ability to cross into the brain without losing reactivation capability. To bypass the blood
brain barrier (BBB), chemists need to make oximes that are small and lipophilic, because of the
BBBs ability to efflux large and small molecular weight compounds that are water soluble. It is
estimated that the blood brain barrier prevents >98% of hydrophilic small and large molecules
from crossing into the brain (Djupesland et al., 2014; Pardridge, 2012). Therefore, to pass
through the BBB, it is critical for a compound to be small and lipophilic.

To bypass the poor blood brain barrier penetration of oximes, delivery of the oxime
intranasally, as opposed to intramuscularly, has been an emerging technique and achieved
significant success at preventing CNS damage (Krishnan et al., 2016).What makes intranasal
delivery an effective method of administration is the rich vascular supply of the nasal cavity, thus
providing a speedy delivery from nose to brain and therefore a potentially rapid onset of
therapeutic effects. This vascular supply is primarily from the opthalamic artery, the
sphenopalatine artery, and the facial artery (Lochhead and Thorpe, 2011). Transport into the
brain from the nasal cavity bypasses the BBB, thus allowing molecules with various
physicochemical characteristics entry into an otherwise restricted area. Absorption can occur via
the olfactory or trigeminal pathway. The olfactory nerve has direct contact with various brain
structures and the upper portions of the nasal cavity, providing a direct contact between the
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environment and the brain (Djupesland et al., 2014). The trigeminal nerve has innervations that
arise from the pons and brainstem and project all the way to the nasal epithelium and olfactory
bulb from its multiple branches (Lochhead and Thorpe, 2011). The processes of absorption into
the brain can take place via different transport mechanisms, such as intracellular transport (i.e.,
being transported via anterograde transport on the axons of the olfactory and trigeminal nerve
components via endocytosis) and extracellular transport (absorption from blood or lymph, or
diffusion from perineural spaces into the brain) (Lochhead and Thorpe, 2011). Being able to
administer an antidote that can bypass the BBB and provide a rapid therapeutic onset that can
protect against CNS damage would be a huge upgrade to the current therapeutic regimen against
OPs.

Materials and Methods
Chemicals
The organophosphate used for this in vivo study was the sarin surrogate nitrophenyl
isopropyl methylphosphonate (NIMP). It was synthesized by the late Dr. Howard Chambers and
originally described in Ohta et al. (2006) and characterized in our laboratories (Meek et al.,
2012). The novel oxime used in this study was oxime 20, also synthesized by the late Dr.
Howard Chambers and originally described in Chambers et al. (2013). 2-pyridinium aldoxime
(2-PAM), the currently FDA-approved oxime reactivator in the United States, was used as the
comparison oxime and was purchased from Sigma Aldrich Chemical Company (St. Louis, MO).

Animals
Adult male Sprague Dawley rats (Crl:CD(SD)BR) at postnatal day (PND) 70 were
purchased from Envigo RMS, Inc. and housed in AAALAC accredited facilities at Mississippi
State University. All animals were held in temperature-controlled environments with a 12-hour
101

light-dark cycle, used Envigo 70-90 Sani Chips, laboratory grade bedding and had free access to
Envigo Rodent Diet (18% protein laboratory rat chow) and tap water. Procedures performed for
this research received prior approval by the Mississippi State University Animal Care and Use
Committee.

Treatment Paradigm
Four rats were used for this experimental paradigm. One rat received vehicle (Multisol, a
biocompatible solvent consisting of 48.5% water, 40% propylene glycol, 10% ethanol, and 1.5%
benzyl alcohol) to serve as vehicle control while three rats received a subcutaneous dose of
NIMP. Each subcutaneous administration was delivered in the back of the neck as performed
previously (Chambers et al., 2016). One rat received NIMP alone while the other two rats were
to receive intranasal oxime therapy. The dose of NIMP resulted in 70-75% brain AChE
inhibition at 1hr following OP challenge (see Figure 4-1 for time course of NIMP brain AChE
inhibition). This dose was determined to be 0.275mg/kg, which is a little lower than previous sub
lethal studies performed in our laboratory of NIMP (0.3mg/kg) which resulted in 80-85% brain
AChE inhibition at 1hr (Chambers et al., 2013). Higher levels of inhibition would have produced
severe cholinergic signs, making the intranasal procedure difficult to complete. This study
wanted to determine proof of principle that intranasal delivery could consistently reduce brain
AChE inhibition. The inhibition observed was high enough to observe a therapeutic benefit but
low enough to allow for consistent and reproducible oxime intranasal delivery. Each challenge of
NIMP was given 20 minutes apart. Five repetitions were completed for each treatment group.

Intranasal Procedure
At one hour post vehicle or NIMP administration, the animals were deeply anesthetized
with 5% isoflurane and placed in the supine position. An intracatheter device (provided by Impel
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NeuroPharma) was inserted into the nasal cavity where 10μl of either oxime (at a dose of
1.46µmoles/kg delivered in Multisol) or vehicle control (Multisol) was delivered bilaterally onto
the olfactory epithelium in both nostrils.

Tissue Collection and Preparation
After the intranasal administration procedure was complete, animals were euthanized by
decapitation at a nominal time zero (i.e., euthanized as quickly as possible), 5 minutes post
oxime administration, or 10 minutes post oxime administration. The brains were quickly
removed from the skull, washed with 0.9% saline and placed in a brain tissue dissection block.
Brains were sliced coronally into three pieces: forebrain, midbrain, and hindbrain. These slices
were snap frozen in liquid nitrogen and stored at -80°C until they were assayed. Brain slices
were homogenized separately, and immediately prior to the assay, utilizing a motorized
homogenizer in 50mM Tris HCl buffer (pH 7.4 25°C) at a stock solution of 40mg/ml wet weight
equivalent and were maintained at 4°C.

Measurement of Cholinesterase Activity
AChE activity was measured in all brain slices by performing a continuous
spectrophotometric essay. In a water bath (37°C), 100μl of brain homogenate was added to a test
tube containing 1900μl of 50mM Tris HCl buffer (pH 7.4 25°C) for a final concentration of
1.8mg of homogenate/ml. Following this, 125μl of 5,5’-dithio bis(2-nitrobenzoic acid) (DTNB,
FC 1.38mM) was delivered and the reaction was initiated by the addition of 50μl of
acetylthiocholine (ATCh in EtOH, FC 2.3mM). The contents of the tube were vortexed
thoroughly and immediately transferred to a cuvette and placed in a Thermo Scientific Biomate 3
spectrophotometer where absorbance values (A) were measured at 412nm and the slope was
calculated from the absorbance measured over two minutes. The absorbance values are directly
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proportional to the amount of substrate hydrolyzed by AChE. The percentage of AChE
inhibition was calculated as described in chapter 2.

Statistical Methods
The effect of treatment, time, and brain section on absorbance was assessed using a
generalized linear mixed model with PROC MIXED in SAS for Windows (SAS Institute, Inc.,
Cary, NC). Fixed effects included treatment, time, brain section, and all two-way and three-way
interactions. Rat within replicate and replicate were included as random effects. In the case of a
significant three-way interaction term, LSMESTIMATE statements were used to make pairwise
comparisons between treatments at each combination of time and brain section, between time
points for each combination of treatment and brain section, and between brain sections for each
combination of time and treatment. The SIMULATE option was used to adjust p-values for
multiple comparisons for each set of pairwise comparisons. The distribution of residuals was
evaluated to assess if the assumptions of normality and homoscedasticity had been met. An
alpha level of 0.05 was used to determine statistical significance.
Results
Results indicated that animals receiving novel oxime 20 showed a statistically significant
difference in AChE absorbance in the forebrain and midbrain (p<0.05) when compared to NIMP
alone treated animals and animals that received 2-PAM at the nominal time zero time point
(Figure 4-2 and Figure 4-3). 2-PAM did not differ from NIMP alone treated animals at the
nominal time zero time point for any of the brain regions, indicating limited entry into the brain.
For the 5 minute time point, animals receiving either oxime 20 or 2-PAM showed a statistically
significant difference (p<0.05) in AChE absorbance values when compared to NIMP alone
treated animals in the forebrain (Figure 4-5) but no significant differences were detected between
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the two oximes or in other brain regions (Figure 4-6 and Figure 4-7). No significant differences
were detected in AChE absorbance values between the two oximes and NIMP alone treated
animals during the ten minute time point in any brain region (Figures 4-8, 4-9, and 4-10).

Discussion
To improve the amount of oxime that can enter into the brain and reactivate OP inhibited
brain AChE, intranasal delivery of oximes was investigated as a potential alternate route of
administration. Despite the limited number of animals used in this study, novel oxime 20
indicated rapid entry into the brain. Oxime 20 was statistically significantly different than NIMP
alone treated animals and 2-PAM treated animals at the nominal time zero point, indicating more
reactivation has occurred with oxime 20 and that less AChE inhibition is present. This could be
due to the fact that oxime 20 is significantly more lipophilic than 2-PAM (Chambers et al.,
2013). This is further supported by the fact that by five minutes 2-PAM and novel oxime 20
absorbance values in the forebrain were not statistically different from each other but were
statistically significantly different from NIMP alone treated animals. Interestingly, this was the
only brain region that showed differences between NIMP alone treated animals in the 5 minute
time point. Additionally, no significant differences were observed in any brain region when the
animals were sacrificed at 10 minutes (Figures 4-8, 4-9, and 4-10) after oxime administration nor
were significant differences observed in the hindbrain for any time point (Figures 4-4, 4-7, and
4-10). The lack of significant differences in the hindbrain could be explained by the fact that it is
the most distal region from the site of administration (the olfactory bulb) and that most of the
oxime has interacted with AChE in other brain regions or that the oxime was removed from the
brain and entered into systemic circulation.
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Nevertheless, we have demonstrated proof of principle that intranasal delivery can be a
viable route of oxime administration to bypass the blood brain barrier. Both oximes entered into
the brain within a couple of minutes while oxime 20 appeared to enter faster, indicating a wider
window of effectiveness compared to 2-PAM. Future studies will need to investigate if multiple
administrations of intranasal oxime delivery are well tolerated, thus potentially increasing the
duration of oxime into the brain and if the more distal brain regions can be reached. In this study,
a single oxime administration did not appear to be very effective as most of the data were not
statistically significant. It is important to note that a limited number of animals were used and
thus it is difficult to draw definitive conclusions. These initial, preliminary results are quite
promising and warrant future investigations. Future experiments involving lethal doses of nerve
agent, multiple oxime administrations, and neuropathology staining would be a better indicator
of intranasal oxime effectiveness.

Conclusion
Intranasal delivery of oximes would be of great value to medical and military personnel.
The risk of long term brain damage after exposure to OPs is of significant concern. Being able to
effectively attenuate the AChE inhibition in the brain, which is the first step to seizure onset, is
paramount to preventing seizures and brain damage. The simplicity of use and ability to rapidly
administer an oxime that can bypass the blood brain barrier and attenuate high AChE inhibition
makes this treatment modality an attractive adjunct to the current therapeutic regimen. The use of
intranasal oxime therapy in conjunction with an anticonvulsant could drastically improve CNS
protection by providing multiple methods in treating OP induced neurotoxicity.
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Figure 4.1

Brain acetylcholinesterase (AChE) inhibition time course of NIMP 0.275mg/kg
delivered subcutaneously.
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Figure 4.2
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Acetylcholinesterase (AChE) absorbance of the forebrain following exposure to
NIMP 0.275mg/kg (NI.275). Treatment groups are NIMP + oxime 20 (NI+OX20)
and NIMP + 2-PAM (NI+2-PAM). Oximes were administered one hour post
NIMP exposure and animals were sacrificed as quickly as possible to yield a
nominal time zero. Data are expressed as mean ± SEM. N=5 animals for each
treatment group. p*≤0.05 when compared to NIMP; p#≤0.05 when compared to
NI+2-PAM.
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Acetylcholinesterase (AChE) absorbance of the midbrain following exposure to
NIMP 0.275mg/kg (NI.275). Treatment groups are NIMP + oxime 20 (NI+OX20)
and NIMP + 2-PAM (NI+2-PAM). Oximes were administered one hour post
NIMP exposure and animals were sacrificed as quickly as possible to yield a
nominal time zero. Data are expressed as mean ± SEM. N=5 animals for each
treatment group. p*≤0.05 when compared to NIMP; p#≤0.05 when compared to
NI+2-PAM.
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Figure 4.4

NI.275

NI+OX20

NI+2-PAM

Acetylcholinesterase (AChE) absorbance of the hindbrain following exposure to
NIMP 0.275mg/kg (NI.275). Treatment groups are NIMP + oxime 20 (NI+OX20)
and NIMP + 2-PAM (NI+2-PAM). Oximes were administered one hour post
NIMP exposure and animals were sacrificed as quickly as possible to yield a
nominal time zero. Data are expressed as mean ± SEM. N=5 animals for each
treatment group.
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Figure 4.5

NI.275

NI+OX20

NI+2-PAM

Acetylcholinesterase (AChE) absorbance of the forebrain following exposure to
NIMP 0.275mg/kg (NI.275). Treatment groups are NIMP + oxime 20 (NI+OX20)
and NIMP + 2-PAM (NI+2-PAM). Oximes were administered one hour post
NIMP exposure and animals were sacrificed five minutes post oxime
administration. Data are expressed as mean ± SEM. N=5 animals for each
treatment group. p*≤0.05 when compared to NIMP
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Figure 4.6

NI.275

NI+OX20

NI+2-PAM

Acetylcholinesterase (AChE) absorbance of the midbrain following exposure to
NIMP 0.275mg/kg (NI.275). Treatment groups are NIMP + oxime 20 (NI+OX20)
and NIMP + 2-PAM (NI+2-PAM). Oximes were administered one hour post
NIMP exposure and animals were sacrificed five minutes post oxime
administration. Data are expressed as mean ± SEM. N=5 animals for each
treatment group.
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Figure 4.7

NI.275

NI+OX20

NI+2-PAM

Acetylcholinesterase (AChE) absorbance of the hindbrain following exposure to
NIMP 0.275mg/kg (NI.275). Treatment groups are NIMP + oxime 20 (NI+OX20)
and NIMP + 2-PAM (NI+2-PAM). Oximes were administered one hour post
NIMP exposure and animals were sacrificed five minutes post oxime
administration. Data are expressed as mean ± SEM. N=5 animals for each
treatment group.
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Figure 4.8

NI.275

NI+OX20

NI+2-PAM

Acetylcholinesterase (AChE) absorbance of the forebrain following exposure to
NIMP 0.275mg/kg (NI.275). Treatment groups are NIMP + oxime 20 (NI+OX20)
and NIMP + 2-PAM (NI+2-PAM). Oximes were administered one hour post
NIMP exposure and animals were sacrificed ten minutes post oxime
administration. Data are expressed as mean ± SEM. N=5 animals for each
treatment group.
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Figure 4.9

NI.275

NI+OX20

NI+2-PAM

Acetylcholinesterase (AChE) absorbance of the midbrain following exposure to
NIMP 0.275mg/kg (NI.275). Treatment groups are NIMP + oxime 20 (NI+OX20)
and NIMP + 2-PAM (NI+2-PAM). Oximes were administered one hour post
NIMP exposure and animals were sacrificed ten minutes post oxime
administration. Data are expressed as mean ± SEM. N=5 animals for each
treatment group.
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Figure 4.10

NI.275

NI+OX20

NI+2-PAM

Acetylcholinesterase (AChE) absorbance of the hindbrain following exposure to
NIMP 0.275mg/kg (NI.275). Treatment groups are NIMP + oxime 20 (NI+OX20)
and NIMP + 2-PAM (NI+2-PAM). Oximes were administered one hour post
NIMP exposure and animals were sacrificed ten minutes post oxime
administration. Data are expressed as mean ± SEM. N=5 animals for each
treatment group.
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CHAPTER V
CONCLUSION
Organophosphate pesticides represent a major public health problem and have been for
several decades. Self ingestion of OP pesticides has represented a significant portion of suicide
attempts in undeveloped countries for several decades. In India, from 2000-2002, OP pesticide
poisoning accounted for 40.5% of committed suicides (Prasad et al., 2006), while in Asia they
represented two thirds of the self ingested pesticide cases (Eddleston, 2000). Unfortunately, this
trend of poisoning continues to be a problem. Pesticide self ingestion, including self ingestion
with OPs, continues to be the suspected cause of at least 200,000 deaths every year (Eddleston
and Chowdhury, 2016). The diversity in OP pesticide structures, high body load of OP after self
ingestion and ill equipped medical facilities in these areas present significant challenges to
clinicians to effectively treat their patients.
Despite being banned for use in warfare, OP nerve agents are still used to carry out
assassination attempts and to commit terrorist attacks. The use of nerve agents by the Syrian
regime on the battlefield of Syria, the recent assassination of King Jong Nam by the North
Korean government using the nerve agent VX, and the assassination attempt on a former Russian
intelligence officer orchestrated by the Russian government using a new brand of nerve agent
called Novichok indicate the willingness of nation states to use nerve agents to carry out their
goals. The effectiveness of nerve agents and apparent lack of concern that governments have for
international law can certainly bolster terrorist groups and other individuals to use such agents.
Unfortunately, the widely available synthesis and development of some of the nerve agents in the
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open literature (Holmstedt, 1951; Bryant et al., 1960; Tammelin, 1957, Tammelin, 1957) poses
significant security challenges for law enforcement and security personnel, making these
compounds a likely threat for years to come.
Oxime reactivator treatment for OPs has remained largely unchanged. 2-PAM, HI-6,
TMB-4, MMB-4, and obidoxime were synthesized in the 1950s and 1960s. 2-PAM, TMB-4 and
obidoxime are the only oximes to have been used in a clinical setting despite thousands of
oximes being synthesized since their inception. The poor blood brain barrier penetration and the
lack of effectiveness against structurally different OPs among these current oxime platforms are
well verified (Eyer and Worek, 2007; Musilek et al., 2009; Worek et al., 2010). Development of
new oxime reactivators that are neuro-protective and broad spectrum are desperately needed to
improve the antidotal treatment against OPs.
Our novel phenoxyalkyl pyridinium oximes have shown promise as brain penetrating
reactivators of AChE to multiple OP chemistries, attenuating OP induced brain damage, seizure
like activity, and increasing survival when compared to 2-PAM (Dail et al., 2019; Pringle et al.,
2018; Chambers et al., 2016, Chambers et al., 2016, Chambers et al., 2016, Chambers et al.,
2013). While the proposed mechanism of action of oximes is reactivation of AChE, research
suggests that there are other non-direct mechanisms of oximes that can lead to a therapeutic
benefit. Oxime interaction with cholinergic receptors is a verified phenomenon (Amitai et al.,
1980; Kuhnen-Clausen et al., 1983; Kloog et al., 1986) and has been suggested to play an
important role in attenuating OP toxicity and lethality despite the evidence of low AChE
reactivation (Melchers et al., 1991; Van Helden et al., 1991).
The primary goal of this research was to investigate an alternative oxime mechanism that
may be contributing to the increased survival seen with our novel oximes. This research focused
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on the reactivation of serum butyrylcholinesterase (BChE) as a potential novel therapeutic target.
Reactivation of serum BChE could increase the detoxication of circulating OP molecules, thus
less OP can reach critical target areas and cause toxicity. Additionally, this research investigated
intranasal delivery of oximes as an alternative method of oxime administration. Traditionally,
oximes are administered intramuscularly (IM). While IM administration of oximes is effective at
reactivating peripheral AChE, very little oxime can enter into the brain and reactivate CNS
inhibited AChE because of their inability to effectively cross the blood brain barrier. Delivery of
the oximes intranasally can provide a novel way to allow more oxime into the brain and attenuate
OP induced neurotoxicity.
In the first part of the study, a well verified reactivation assay was performed to assess
oxime-mediated BChE reactivation in vitro in rat, human, and guinea pig serum. Several tested
novel oximes were used and compared to the current oxime platforms 2-PAM, HI-6, obidoxime,
TMB-4, and MMB-4 after inhibition by structurally different OPs. These OPs consisted of nerve
agent surrogates for sarin, VX, and cyclosarin and of the insecticidal OP oxons paraoxon,
phorate oxon, and phorate oxon sulfoxide. Data from these experiments revealed several
effective BChE reactivators. Novel oxime 15 was determined to be the most effective for OP
inhibited rat BChE. Demonstrating >75% reactivation after inhibition by the sarin surrogate
PIMP, the VX surrogate NEMP, and paraoxon. Novel oxime 20 was determined to be the most
effective oxime for OP inhibited human BChE. Oxime 20 demonstrated impressive broad
spectrum efficacy towards 6 of the 8 OP compounds tested, reaching greater than 70%
reactivation for sarin and VX surrogates, and the phorate metabolites (phorate oxon and phorate
oxon sulfoxide). 2-PAM, TMB-4, MMB-4, obidoxime and HI-6 were poor BChE reactivators.
All oximes were poor reactivators of OP inhibited guinea pig BChE.
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The second part of this study investigated oxime reactivation kinetics for novel oxime 15,
novel oxime 20, and 2-PAM for electric eel AChE and rat and human serum BChE after
inhibition by the sarin surrogate NIMP and the insecticidal metabolite paraoxon. Results
indicated that both novel oxime 15 and oxime 20 were more effective reactivators of NIMP and
paraoxon inhibited electric eel AChE when compared to 2-PAM, indicated by the kr2.
Additionally, novel oxime 20 was a more effective reactivator of NIMP inhibited human BChE
than both novel oxime 15 and 2-PAM. While the intrinsic reactivity of our oximes was lower for
rat inhibited BChE compared to the other species, the oximes displayed high affinity for the
paraoxon inhibited enzyme (KD less than 1µM) and thus proved to be efficient reactivators.
Oxime 20 also demonstrated efficacy towards NIMP inhibited rat BChE while oxime 15 and 2PAM did not. Oxime 20 demonstrated an ability to reactivate both NIMP and paraoxon inhibited
AChE and BChE.
The third part of this study investigated intranasal delivery of oximes as an alternative
route of administration to treat OP inhibited brain AChE. This study demonstrated that intranasal
delivery of either novel oxime 20 or 2-PAM were able to reduce NIMP inhibited brain AChE in
select brain regions within a few minutes. Oxime 20 reached the brain faster than 2-PAM,
indicating a wider range of effectiveness. However, neither oxime was able to effectively
attenuate brain AChE inhibition in more distal brain regions such as the hindbrain. Nevertheless,
the preliminary results of this study showed proof of principle that intranasally delivered oximes
could be an effective route of administration to attenuate brain AChE inhibition.
The data presented in this study demonstrated that our novel oximes were more effective
BChE reactivators than the current oxime therapeutics. These data could explain the increased
survivability and cessation of seizure like behavior that was seen with novel oxime 20 in vivo
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when compared to 2-PAM after exposure to lethal levels of sarin and VX surrogates and
paraoxon in the rat model (Chambers et al., 2016). Novel oxime 20 was a much more effective
reactivator of sarin surrogate-, VX surrogate-, and paraoxon-inhibited rat BChE than 2-PAM (see
Chapter 2). This increase in BChE reactivation should theoretically detoxify additional OP
molecules in the circulation, thus a smaller amount of OP can enter into the brain and cause
seizures and inhibit important respiratory control centers. It has also been demonstrated that
oxime 20 can reactivate AChE (see Chapters 3 and 4). It may be the case that this dual capability
of reactivating both AChE and BChE may be an important mechanism contributing to the
therapeutic benefit of oxime 20. While more studies need to be completed to more accurately
investigate the efficiency of AChE and BChE reactivation by oxime 20 in other animal models
and human enzyme, as well as the efficacy of intranasally delivered oximes, both of these
alternative mechanisms show promise as potential alternatives to increase the neuroprotection
and broad spectrum capabilities of oxime reactivators that are desperately needed for treating OP
nerve agents and insecticides.
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